

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

July 08, 2026

To The Manager, Listing Department National Stock Exchange of India Limited Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 543960
--	--

Sub.: Newspaper Advertisement - for Notice of 41st Annual General Meeting

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of the newspaper advertisements published for the information of the shareholders, in compliance with the applicable provisions of the SEBI Listing Regulations and the Companies Act, 2013, read with the rules made thereunder. The advertisements, inter alia, contain information regarding the Company's 41st Annual General Meeting, notice of candidature for the office of Director, the record date, and the availability of the e-voting facility.

The Details of the publications are as follows:

Sr. No.	Newspaper	Language	Editions
1	Financial Express	English	All
2	Financial Express	Gujarati	Ahmedabad

Kindly take the above on records.

Thanking you,

For Concord Biotech Limited

Paritosh Trivedi
Company Secretary & Compliance Officer
ACS 63623

Encl.: As above



Utkarsh Small Finance Bank
Aapki Ummeed Ka Khaata
 (A Scheduled Commercial Bank)

UTKARSH SMALL FINANCE BANK LIMITED
 CIN: L65992UP2016PLC082804

Registered Office: Utkarsh Tower, NH - 31 (Airport Road), Sehmapur, Kazi Sarai, Harhua, Varanasi, Uttar Pradesh. PIN - 221105.
 Tel. No.: +91-542-6605555 | Email: shareholder@utkarsh.bank.in
 Website: www.utkarsh.bank.in

NOTICE IS HEREBY GIVEN THAT THE TENTH (10th) ANNUAL GENERAL MEETING ("AGM") OF THE MEMBERS OF UTKARSH SMALL FINANCE BANK LIMITED ("USFBL" OR "THE BANK") WILL BE HELD ON TUESDAY, AUGUST 04, 2026 AT 2.30 P.M., INDIAN STANDARD TIME ("IST") THROUGH VIDEO CONFERENCE ("VC") / OTHER AUDIO-VISUAL MEANS ("OAVM") TO TRANSACT THE BUSINESS AS SET OUT IN THE NOTICE OF THE AGM WHICH WILL BE CIRCULATED FOR CONVENING THE AGM.

- This is in compliance with the applicable provisions of the Companies Act, 2013 and the Rules made thereunder and Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") read with the Ministry of Corporate Affairs, Government of India ("MCA") Circular No. 03/2025 dated September 22, 2025 (in continuation with the Circulars issued earlier in this regard) ("MCA Circulars") and the SEBI vide various circulars issued in this regard ("SEBI Circulars") has permitted companies to hold AGM through VC or OAVM, without physical presence of the Members at a common venue.
- The Notice of AGM and Annual Report of the Bank for the Financial Year 2025-26 will be sent electronically to those Members whose e-mail addresses are registered with the Bank/ Registrar and Transfer Agent ("RTA") i.e. KFin Technologies Limited ("KFIN") or with the Depository Participant ("DP"). The Bank shall send a physical copy of the Annual Report to those Members who request for the same at shareholder@utkarsh.bank.in mentioning their DP ID and Client ID.
- All the shares of the Bank are Dematerialized form. Members holding shares in Dematerialized form and who have not registered/updated their e-mail addresses with the Depository Participant are requested to register/update their e-mail addresses and mobile numbers with their DP by following procedures prescribed by their DP.
- The Bank has engaged the services of National Securities Depository Limited ("NSDL") for the purpose of providing e-voting facility to its Members to cast their votes on all resolutions set out in the Notice of 10th AGM. The details such as manner of (i) registering/updating email addresses, (ii) casting vote through remote e-voting/e-voting during the AGM and (iii) attending the AGM through VC/OAVM will be set out in the Notice of the AGM, which will be circulated through e-mail. The remote e-voting facility would be available during the following period:

Commencement of e-Voting	Saturday, August 01, 2026 at 9:00 a.m. (IST)
End of e-Voting	Monday, August 03, 2026 at 5:00 p.m. (IST)

- The Members are requested to carefully read all the Notes set out in the Notice of 10th AGM (being sent electronically) and particulars, instructions for joining AGM and manner of casting vote through remote e-voting or e-voting at the AGM.
- The Notice of 10th AGM and the Annual Report for Financial Year 2025-26 will also be made available on the Bank's website www.utkarsh.bank.in and websites of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and also on the website of NSDL at www.evoting.nsdl.com

For Utkarsh Small Finance Bank Limited
 Sd/-
Muthiah Ganapathy
 Company Secretary & Compliance Officer

Date: July 08, 2026
 Place: Mumbai

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES OR UNITS NOR IS IT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES OF CULT.FIT LIMITED (FORMERLY CULT.FIT PRIVATE LIMITED AND CUREFIT HEALTHCARE PRIVATE LIMITED) ON THE MAIN BOARD OF BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE") AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT



CULT.FIT LIMITED

(Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)

Our Company was originally incorporated as 'Cure Fit Healthcare Private Limited' as a private limited company under the Companies Act, 2013, at Bengaluru, Karnataka, pursuant to a certificate of incorporation dated May 24, 2016 issued by the Registrar of Companies, Central Registration Centre ("CRC"). Subsequently, the name of the Company changed to 'CureFit Healthcare Private Limited' pursuant to a Board resolution dated September 22, 2016 and special resolution passed by the Shareholders dated September 23, 2016 on account of re-branding 'CureFit' for branding and marketing purposes, and a fresh certificate of incorporation dated November 16, 2016 issued by the Registrar of Companies, Karnataka at Bangalore. Further, the name of the Company changed to 'Cult.Fit Private Limited' pursuant to a Board resolution dated March 3, 2026 and special resolution passed by the Shareholders dated March 13, 2026 on account of re-branding 'Cult.Fit' to reflect our Company's business identity and branding strategy, and a fresh certificate of incorporation dated April 29, 2026 issued by the Registrar of Companies, Central Processing Centre ("CPC"). Our Company was thereafter converted into a public limited company pursuant to a resolution passed by our Board on June 16, 2026 and resolution passed by our Shareholders on June 17, 2026 and the name of our Company changed to 'Cult.Fit Limited'. A fresh certificate of incorporation dated June 25, 2026 was issued by the CPC pursuant to conversion to a public limited company. For further details, including details in relation to the changes in the registered office of our Company, see "History and Certain Corporate Matters - Changes in our Registered Office" on page 298 of the draft red herring prospectus dated July 6, 2026 ("DRHP").

Corporate Identity Number: U74999TN2016PLC176669

Registered Office: 3rd Floor, Plot No. 269, Sy. No. 439/1B, Rajiv Gandhi Road, Chennai, Sholinganallur, Saidapet, Kanchipuram - 600 119, Tamil Nadu, India
 Corporate Office: Curefit HQ, 17/17C - BDA, 18th Cross, Sector-3, HSR Layout, Bengaluru - 560 102, Karnataka
 Tel: +91 9167219018. Website: www.cult.fit. Contact person: Siddharth Sharma, Company Secretary and Compliance Officer. E-mail: secretarial@cult.fit

OUR COMPANY IS A PROFESSIONALLY MANAGED COMPANY AND DOES NOT HAVE AN IDENTIFIABLE PROMOTER

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF CULT.FIT LIMITED ("OUR COMPANY" OR "THE COMPANY") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹9,590.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 178,609,200 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS CONSISTING OF UP TO 24,664,113 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MACRITCHE INVESTMENTS PTE. LTD. UP TO 19,597,242 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY FITNESS FIRST LUXEMBOURG S.C.A., UP TO 17,038,233 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY IDG VENTURES INDIA FUND III LLC, UP TO 15,862,353 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY TATA DIGITAL PRIVATE LIMITED, UP TO 11,036,131 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY CHIRATAE TRUST REPRESENTED BY ITS TRUSTEE VISTRA ITC (INDIA) LIMITED AND ACTING THROUGH ITS INVESTMENT MANAGER, NAIGAMA INVESTMENT MANAGER LLP, UP TO 9,915,315 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SCHROEDERS CAPITAL PRIVATE EQUITY ASIA MAURITIUS IV LIMITED, UP TO 7,912,322 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY TWENTY NINE CAPITAL PARTNERS LIMITED PARTNERSHIP (ACTING AT ALL TIMES THROUGH ITS GENERAL PARTNER, TWENTY NINE CAPITAL PARTNERS (GENERAL PARTNER) LIMITED), UP TO 6,532,434 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ACCEL INDIA V (MAURITIUS) LIMITED, UP TO 6,165,096 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ACCEL INDIA IV (MAURITIUS) LIMITED, UP TO 6,664,412 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY EPIQ CAPITAL B. L.P., UP TO 4,130,615 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY KALAARI CAPITAL PARTNERS III, LLC, UP TO 3,278,461 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY KALAARI CAPITAL PARTNERS OPPORTUNITY FUND, LLC, UP TO 2,316,969 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VALECHA INVESTMENTS PRIVATE LIMITED, UP TO 1,660,588 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SATYADHARMA INVESTMENTS AND TRADING COMPANY PRIVATE LIMITED, UP TO 1,024,116 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY CASTLE INVESTMENT AND INDUSTRIES PRIVATE LIMITED, UP TO 941,781 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ANANTH SANKARANARAYANAN FAMILY TRUST, UP TO 816,061 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SUN N SAND HOTELS PRIVATE LIMITED, UP TO 729,958 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VENKATESH INVESTMENT AND TRADING COMPANY PRIVATE LIMITED, UP TO 686,412 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ENDIYA SEED CO-CREATION FUND (A SCHEME OF ENDIYA TRUST, ACTING THROUGH ITS TRUSTEE, ENDIYA TRUSTEE PRIVATE LIMITED), UP TO 641,784 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY EXTREME BRANDS LLP, UP TO 486,609 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ONYX SHAREHOLDERS LLC, UP TO 363,065 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY DOLI TRADING AND INVESTMENTS PRIVATE LIMITED (THE "INVESTOR SELLING SHAREHOLDERS"), UP TO 16,021,780 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MUKESH BANSAL, UP TO 10,212,631 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY BRUNO EDUARD RASCHLE, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY JAMES SHA, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ASAF AVIDAN ANTONIR, UP TO 907,287 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY KARAN HARESH MOTWANI, UP TO 907,284 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY NEHA KARAN MOTWANI, UP TO 633,813 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY HRITHIK RAKESH ROSHAN, UP TO 610,000 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY GUL RAMCHAND ADVANI, UP TO 467,333 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VILAS S DHAR, UP TO 211,245 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MUKUL DEORAS, UP TO 138,016 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VIJAY KUMAR TAPARIA, UP TO 49,849 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SHRADHA SHETH, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY PRASHANT SUDHAKAR MACHWE, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY NIKHIL KAKKAR (THE "INDIVIDUAL SELLING SHAREHOLDERS") (COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS", AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE", AND TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A PRE-IPO PLACEMENT OF SPECIFIED SECURITIES AGGREGATING UP TO ₹1,900.00 MILLION, AS MAY BE PERMITTED UNDER THE APPLICABLE LAW, AT ITS DISCRETION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE PRIOR TO THE COMPLETION OF THE OFFER. OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER, OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND THE PROSPECTUS AND DETAILS OF THE PRE-IPO PLACEMENT, IF ANY, SHALL BE REPORTED TO THE STOCK EXCHANGES WITHIN 24 HOURS OF SUCH TRANSACTIONS, IN ACCORDANCE WITH REGULATION 54 OF THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid/ Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company in consultation with the BRLMs and each of the Selling Shareholders, may for reasons to be recorded in writing, extend the Bid/ Offer Period for a minimum of one Working Day, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and Intimation to Self-Certified Syndicate Banks ("SCSBs"), the Designated Intermediaries (as defined hereinafter) and the Sponsor Banks, (as defined hereinafter) as applicable.

This is an Offer in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. This Offer is being made through the Book Building Process in compliance with Regulation 6(2) of the SEBI ICDR Regulations wherein in terms of Regulation 32(2) of the SEBI ICDR Regulations not less than 75% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") and such portion of the "QIB Portion" provided that our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"). 40% of the Anchor Investor Portion shall be reserved as follows: (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds and Life Insurance Companies and Pension Funds at or above the price at which Equity Shares will be allocated to Anchor Investors ("Anchor Investor Allocation Price") in accordance with the SEBI ICDR Regulations and any under-subscription of 6.67% of the Anchor Investor Portion reserved for Life Insurance Companies and Pension Funds, such under-subscribed portion may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be Allotted to QIBs, then the entire Bid Amount (as defined hereinafter) will be refunded forthwith. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Offer shall be available for allocation to NBIs of which (a) one third portion shall be reserved for Bidders with application size of more than ₹0.20 million and up to ₹1.00 million; and (b) two-thirds of the portion shall be reserved for Bidders with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to Bidders in other sub-category of the NBIs in accordance with SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, not more than 10% of the Offer shall be available for allocation to Retail Individual Bidders ("RIB") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts (including UPI ID (defined hereinafter) in case of UPI Bidders (defined hereinafter) using the UPI Mechanism (defined hereinafter), in which case the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. For details, see "Offer Procedures" on page 536 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP, on July 7, 2026 with the Stock Exchanges and Securities and Exchange Board of India ("SEBI"). Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of publication of this public announcement by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE at www.bseindia.com and NSE at www.nseindia.com, on the website of the Company at www.cult.fit and on the websites of the Book Running Lead Managers ("BRLMs"), i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jeffries.com, www.jmfi.com and www.morganstanley.com, respectively. Our Company invites the public to give their comments on the DRHP filed with SEBI and the Stock Exchanges, with respect to disclosures made in the DRHP. The public is requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Offer on or before 5:00 p.m. on the 21st day from the date of publication of this public announcement in accordance with Regulation 26(2) of the SEBI ICDR Regulations.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" beginning on page 21 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when issued through the RHP, are proposed to be listed on the Stock Exchanges.

For details of the share capital and capital structure and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, please see the section titled "Capital Structure" on page 104 of the DRHP. The liability of the members of our Company is limited by their shares. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on page 298 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER	
					
Axis Capital Limited 1 st Floor, Axis House P.B. Marg Worli Mumbai - 400 025 Maharashtra, India Tel: +91 22 4325 2183 E-mail: cultfitipo@axiscap.in Website: www.axiscapital.co.in Investor Grievance ID: complaints@axiscap.in	Goldman Sachs (India) Securities Private Limited 10 th Floor Ascent-Worli, Sudam Kaku Ahrir Marg, Worli, Mumbai - 400 025 Maharashtra, India Tel: +91 22 6616 9000 E-mail: gs-cultfit@gs.com Website: www.goldmansachs.com Investor Grievance ID: india-client-support@gs.com	Jefferies India Private Limited Level 15, Express Towers, Nariman Point, Mumbai - 400 021, Maharashtra, India Tel: +91 22 4356 6000 E-mail: CultFitIPO@jefferies.com Website: www.jeffries.com Investor Grievance ID: jpl.grievance@jefferies.com	JM Financial Limited 7 th Floor, Energy, Appasaheb Marathe Marg, Prabhadevi Mumbai - 400 025 Maharashtra, India Tel: +91 22 6630 3030 E-mail: cultfitipo@jmfi.com Website: www.jmfi.com Investor grievance ID: grievance_id@jmfi.com	Morgan Stanley India Company Private Limited Atrium, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai - 400 018 Maharashtra, India Tel: +91 22 6118 1000 E-mail: cultfitipo@morganstanley.com Website: www.morganstanley.com Investor Grievance ID: investors_india@morganstanley.com	KFin Technologies Limited 301, The Centrum, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Kurla, Mumbai - 400 070, Maharashtra, India Tel: +91 40 67 16 2222/180034001 E-mail: cultfitipo@kfintech.com Website: www.kfintech.com Investor grievance e-mail: einward.ris@kfintech.com
Contact Person: Pavan Naik SEBI Registration Number: INM00012629	Contact Person: Achint Parmar/Anandkhar Harsh Parekh SEBI Registration Number: INM00011084	Contact Person: Nidhi Rana, Viti Menghrajani SEBI Registration Number: INM00011443	Contact Person: Prachee Dhuri SEBI Registration No.: INM00010361	Contact Person: Adith Herga SEBI Registration No.: INM00011203	Contact Person: M. Murali Krishna SEBI Registration No.: INR00000221

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For CULT.FIT LIMITED
 (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)
 On behalf of the Board of Directors
 Sd/-
Siddharth Sharma
 Company Secretary and Compliance Officer

CULT.FIT LIMITED (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited) is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on July 7, 2026. The DRHP is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.cult.fit and on the websites of the BRLMs, i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jeffries.com, www.jmfi.com and www.morganstanley.com, respectively. Any potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" on page 21 of the DRHP. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, when filed, for making any investment decision.

This announcement is not for publication or distribution to persons in the United States. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act ("Rule 144A") and referred to in the Draft Red Herring Prospectus as "U.S. QIBs", for the avoidance of doubt, the term "U.S. QIBs" does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the Draft Red Herring Prospectus as "QIBs") in one or more transactions exempt from the registration requirements of the U.S. Securities Act; and (ii) outside the United States in "offshore transactions", as defined in, and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.

CONCORD BIOTECH
 Biotech for Mankind...
CONCORD BIOTECH LIMITED
 CIN : L24230GJ1984PLC007440
 Regd. Off.: 1482-86, Trasad Road, Dholka, Ahmedabad - 382225, Gujarat, India
 Tel. No. : +91-79-68138725 | Email : compliance@concordbiotech.com
 Website : https://www.concordbiotech.com

NOTICE OF THE 41ST ANNUAL GENERAL MEETING, BOOK CLOSURE AND REMOTE E-VOTING INFORMATION

Notice is hereby given that the 41st Annual General Meeting ("AGM") of the Members of the Company will be held on **Friday, July 31, 2026 at 12:00 Noon** through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the business as set out in the Notice of AGM.

The Company has sent the Annual Report along with Notice convening 41st AGM on Tuesday, July 07, 2026, through electronic mode to all the Members whose e-mail IDs are registered with the Company's Registrar & Share Transfer Agent, M/s MUFG Intime India Private Limited / Depository Participant(s). In accordance with the provisions of the Companies Act, 2013 ("the Act"), read with the Rules made thereunder and General Circular Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 5, 2020 and subsequent circulars issued in this regard, the latest being 03/2025 dated September 22, 2025, collecti vely referred to as "MCA Circulars", and other applicable circulars issued by the Securities and Exchange Board of India (SEBI) including Circular No. SEBI/HO/CFD/CFD-POD-2/P/CIR/2024/153 dated October 3, 2024 ("SEBI Circulars"), AGM of the Company is being held through VC / OAVM.

In accordance with the aforesaid Circulars, Notice of AGM along with the Annual Report 2025-26 has been sent only by electronic mode to those Members whose e-mail addresses are registered with the Company/ Depositories. The Company has also sent a letter containing the web-link along with the path to access the Annual Report 2025-26 (including the Notice) to the Members whose email addresses are not registered with the Company/ RTA/ Depository Participant(s) pursuant to Regulation 36(1)(b) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (Listing Regulations). Members may note that the Notice of AGM and Annual Report 2025-26 is also available at the Company's website i.e. www.concordbiotech.com, website of Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and on the website of the Central Depository Services (India) Limited (agency providing remote e-voting facility and e-voting facility during the AGM) i.e. www.evotingindia.com. Members can attend and participate in the AGM through the VC / OAVM facility only. The instructions for joining the AGM are provided in the Notice of the AGM. Members attending the meeting through VC / OAVM shall be counted for the purpose of reckoning the quorum as per Section 103 of the Companies Act, 2013.

Notice is also hereby given that pursuant to Regulation 42 of Listing Regulations, the Company has fixed record date as Friday, July 24, 2026 for the purpose of identification of shareholders to whom dividend is to be paid and for the purpose of 41st AGM of the Company. Pursuant to the provisions of Section 108 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended and Regulation 44 of the Listing Regulations, members are provided with the facility to cast their vote electronically through remote e-voting as e-voting during the AGM services provided by the Central Depository Services (India) Limited on all resolutions as set forth in the 41st AGM Notice. The voting rights of the members shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as on Friday, July 24, 2026 ("cut-off date").

The remote e-voting period commences on Tuesday, July 28, 2026 [09:00 A.M. IST] and ends on Thursday, July 30, 2026 [05:00 P.M. IST]. During this period, the Members may cast their vote electronically. The remote e-voting module shall be disabled by the Central Depository Services (India) Limited thereafter. Those Members, who shall be present in the AGM through VC / OAVM facility and had not cast their votes on the Resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.

The members who have cast their votes by remote e-voting prior to the AGM may also attend/ participate in the AGM through VC / OAVM but shall not be entitled to cast their votes again.

Any person, who acquires shares of the Company and becomes a Member of the Company after the Notice has been sent electronically by the Company and holds shares as on the cut-off date, may obtain the log in ID and password by sending a request to helpdesk.helpdesk.evoting@cdsindia.com. However, if he / she is already registered with CDSL for remote e-voting, then he / she can use his/ her existing User ID and password for casting the votes.

The manner of remote e-voting and voting at the AGM by members holding shares in dematerialized mode, physical mode and process to register e-mail addresses for members who have not registered their email addresses is provided in the Notice of the 41st AGM.

In case Member(s) have not registered their e-mail addresses with the Company/ Depository, please follow the below instructions to register e-mail address for obtaining Annual Report and login details for e-voting - Members holding shares in Demat mode can get their e-mail ID registered by contacting their respective Depository Participant or by e-mail to complianceofficer@concordbiotech.com

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdsindia.com or contact at toll free no. 13022109911.

For, **CONCORD BIOTECH LIMITED**
 Sd/- **Paritosh Trivedi**
 Company Secretary & Compliance Officer (ACS : 63623)

Date : July 07, 2026

Place : Ahmedabad



Utkarsh Small Finance Bank
Aapki Ummeed Ka Khaata
 (A Scheduled Commercial Bank)
UTKARSH SMALL FINANCE BANK LIMITED
 CIN: L65992UP2016PLC082804
 Registered Office: Utkarsh Tower, NH - 31 (Airport Road), Sehmalpur, Kazi Sarai, Harhua, Varanasi, Uttar Pradesh, PIN - 221 105.
 Tel. No.: +91-542-6605555 | Email: shareholders@utkarsh.bank.in
 Website: www.utkarsh.bank.in

NOTICE IS HEREBY GIVEN THAT THE TENTH (10th) ANNUAL GENERAL MEETING ("AGM") OF THE MEMBERS OF UTKARSH SMALL FINANCE BANK LIMITED ("USFB" OR "THE BANK") WILL BE HELD ON TUESDAY, AUGUST 04, 2026 AT 2.30 P.M., INDIAN STANDARD TIME ("IST") THROUGH VIDEO CONFERENCE ("VC") / OTHER AUDIO-VISUAL MEANS ("OAVM") TO TRANSACT THE BUSINESS AS SET OUT IN THE NOTICE OF THE AGM WHICH WILL BE CIRCULATED FOR CONVENING THE AGM.

- This is in compliance with the applicable provisions of the Companies Act, 2013 and the Rules made thereunder and Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") read with the Ministry of Corporate Affairs, Government of India ("MCA") Circular No. 03/2025 dated September 22, 2025 (in continuation with the Circulars issued earlier in this regard) ("MCA Circulars") and the SEBI vide various circulars issued in this regard ("SEBI Circulars") has permitted companies to hold AGM through VC or OAVM, without physical presence of the Members at a common venue.
- The Notice of AGM and Annual Report of the Bank for the Financial Year 2025-26 will be sent electronically to those Members whose e-mail addresses are registered with the Bank/ Registrar and Transfer Agent ("RTA") i.e. KFin Technologies Limited ("KFIN") or with the Depository Participant ("DP"). The Bank shall send a physical copy of the Annual Report to those Members who request for the same at shareholders@utkarsh.bank.in mentioning their DP ID and Client ID.
- All the shares of the Bank are Dematerialized form. Members holding shares in Dematerialized form and who have not registered/updated their e-mail addresses with the Depository Participants are requested to register/update their e-mail addresses and mobile numbers with their DP by following procedures prescribed by their DP.
- The Bank has engaged the services of National Securities Depository Limited ("NSDL") for the purpose of providing e-voting facility to its Members to cast their votes on all resolutions set out in the Notice of 10th AGM. The details such as manner of (i) registering/updating email addresses, (ii) casting vote through remote e-voting/e-voting during the AGM and (iii) attending the AGM through VC/OAVM will be set out in the Notice of the AGM, which will be circulated through e-mail. The remote e-Voting facility would be available during the following period:

Commencement of e-Voting	Saturday, August 01, 2026 at 9:00 a.m. (IST)
End of e-Voting	Monday, August 03, 2026 at 5:00 p.m. (IST)

For Utkarsh Small Finance Bank Limited
 Sd/-
Muthiah Ganapathy
 Company Secretary & Compliance Officer

Date: July 08, 2026
 Place: Mumbai

CONCORD BIOTECH
Biotech for Mankind...
CONCORD BIOTECH LIMITED
 CIN : L24230GJ1984PLC007440
 Regd. Off.: 1482-86, Trasad Road, Dholka, Ahmedabad - 382225, Gujarat, India
 Tel. No.: + 91-79-88138725 | Email: compliance@concordbiotech.com
 Website: <https://www.concordbiotech.com>

NOTICE OF THE 41ST ANNUAL GENERAL MEETING, BOOK CLOSURE AND REMOTE E-VOTING INFORMATION

Notice is hereby given that the 41st Annual General Meeting ("AGM") of the Members of the Company will be held on **Friday, July 31, 2026 at 12:00 Noon** through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the business as set out in the Notice of AGM. The Company has sent the Annual Report along with Notice convening 41st AGM on Tuesday, July 07, 2026, through electronic mode to all the Members whose e-mail IDs are registered with the Company's Registrar & Share Transfer Agent, M/s MUFG Intime India Private Limited / Depository Participant(s). In accordance with the provisions of the Companies Act, 2013 ("the Act"), read with the Rules made thereunder and General Circular Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 5, 2020 and subsequent circulars issued in this regard, the latest being 03/2025 dated September 22, 2025, collectively referred to as "MCA Circulars", and other applicable circulars issued by the Securities and Exchange Board of India (SEBI) including Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024 ("SEBI Circulars"). AGM of the Company is being held through VC / OAVM.

In accordance with the aforesaid Circulars, Notice of AGM along with the Annual Report 2025-26 has been sent only by electronic mode to those Members whose e-mail addresses are registered with the Company/ Depositories. The Company has also sent a letter containing the web-link along with the path to access the Annual Report 2025-26 (including the Notice) to the Members whose email addresses are not registered with the Company/ RTA/ Depository Participant(s) pursuant to Regulation 38(1)(b) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations). Members may note that the Notice of AGM and Annual Report 2025-26 is also available at the Company's website i.e., www.concordbiotech.com, website of Stock Exchanges i.e., BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and on the website of the Central Depository Services (India) Limited (agency providing remote e-voting facility and e-voting facility during the AGM) i.e., www.evotingindia.com. Members can attend and participate in the AGM through the VC / OAVM facility only. The instructions for joining the AGM are provided in the Notice of the AGM. Members attending the meeting through VC / OAVM shall be counted for the purpose of reckoning the quorum as per Section 103 of the Companies Act, 2013.

Notice is also hereby given that pursuant to Regulation 42 of Listing Regulations, the Company has fixed record date as Friday, July 24, 2026 for the purpose of identification of shareholders to whom dividend is to be paid and for the purpose of 41st AGM of the Company. Pursuant to the provisions of Section 108 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended and Regulation 44 of the Listing Regulations, members are provided with the facility to cast their vote electronically through remote e-voting as e-voting during the AGM services provided by the Central Depository Services (India) Limited on all resolutions as set forth in the 41st AGM Notice. The voting rights of the members shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as on Friday, July 24, 2026 ("cut-off date").

The remote e-voting period commences on Tuesday, July 28, 2026 (09:00 A.M. IST) and ends on Thursday, July 30, 2026 (05:00 P.M. IST). During this period, the Members may cast their vote electronically. The remote e-voting module shall be disabled by the Central Depository Services (India) Limited thereafter. Those Members, who shall be present in the AGM through VC/OAVM facility and had not cast their votes on the Resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.

The members who have cast their votes by remote e-voting prior to the AGM may also attend/participate in the AGM through VC/OAVM but shall not be entitled to cast their votes again.

Any person, who acquires shares of the Company and becomes a Member of the Company after the Notice has been sent electronically by the Company and holds shares as on the cut-off date, may obtain the log in ID and password by sending a request to helpdesk.evoting@cdsindia.com. However, if he/she is already registered with CDSL for remote e-voting, then he/she can use his/her existing User ID and password for casting the votes.

The manner of remote e-voting and voting at the AGM by members holding shares in dematerialized mode, physical mode and process to register e-mail addresses for members who have not registered their email addresses is provided in the Notice of the 41st AGM.

In case Member(s) have not registered their e-mail addresses with the Company/ Depository, please follow the below instructions to register e-mail address for obtaining Annual Report and login details for e-voting - Members holding shares in Demat mode can get their E-mail ID registered by contacting their respective Depository Participant or by e-mail to complianceofficer@concordbiotech.com


If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting system, you can write an email to helpdesk.evoting@cdsindia.com or contact at toll free no. 18002109911.

For **CONCORD BIOTECH LIMITED**
 Sd/- **Paritosh Trivedi**
 Company Secretary &
 Compliance Officer (ACS : 63623)

Place : Ahmedabad
 Date : July 07, 2026

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES OR UNITS NOR IS IT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA, INITIAL PUBLIC OFFERING OF EQUITY SHARES OF CULT.FIT LIMITED (FORMERLY CULT.FIT PRIVATE LIMITED AND CUREFIT HEALTHCARE PRIVATE LIMITED) ON THE MAIN BOARD OF BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES" IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT



CULT.FIT LIMITED

(Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)

Our Company was originally incorporated as 'Cure Fit Healthcare Private Limited' as a private limited company under the Companies Act, 2013, at Bengaluru, Karnataka, pursuant to a certificate of incorporation dated May 24, 2016 issued by the Registrar of Companies, Central Registration Centre ("CRC"). Subsequently, the name of the Company changed to 'CureFit Healthcare Private Limited' pursuant to a Board resolution dated September 22, 2016 and special resolution passed by the Shareholders dated September 23, 2016 on account of re-branding 'CureFit' for branding and marketing purposes, and a fresh certificate of incorporation dated November 16, 2016 issued by the Registrar of Companies, Karnataka at Bangalore. Further, the name of the Company changed to 'Cult Fit Private Limited' pursuant to a Board resolution dated March 3, 2026 and special resolution passed by the Shareholders dated March 13, 2026 on account of re-branding 'Cult Fit' to reflect our Company's business identity and branding strategy, and a fresh certificate of incorporation dated April 29, 2026 issued by the Registrar of Companies, Central Processing Centre ("CPC"). Our Company was thereafter converted into a public limited company pursuant to a resolution passed by our Board on June 16, 2026 and resolution passed by our Shareholders on June 17, 2026 and the name of our Company changed to 'Cult.Fit Limited'. A fresh certificate of incorporation dated June 25, 2026 was issued by the CPC pursuant to conversion to a public limited company. For further details, including details in relation to the changes in the registered office of our Company, see "History and Certain Corporate Matters - Changes in our Registered Office" on page 295 of the draft red herring prospectus dated July 6, 2026 ("DRHP").

Corporate Identity Number: U74989TN2016PLC176669
 Registered Office: 3rd Floor, Plot No. 269, Sy. No. 439/1B, Rajiv Gandhi Road, Chennai, Sholinganallur, Saidapet, Kanchipuram - 600 119, Tamil Nadu, India
 Corporate Office: CureFit HQ, 17/17C - BDA, 18th Cross, Sector-3, HSR Layout, Bengaluru, - 560 102, Karnataka
 Tel: +91 9187219018; Website: www.cult.fit; Contact person: Siddharth Sharma, Company Secretary and Compliance Officer; E-mail: secretarial@cult.fit

OUR COMPANY IS A PROFESSIONALLY MANAGED COMPANY AND DOES NOT HAVE AN IDENTIFIABLE PROMOTER

INITIAL PUBLIC OFFERING OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF CULT.FIT LIMITED ("OUR COMPANY" OR "THE COMPANY") FOR CASH AT A PRICE OF ₹[•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[•] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[•] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹9,500.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 178,609,200 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS CONSISTING OF UP TO 24,664,113 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY MACRITCHE INVESTMENTS PTE. LTD., UP TO 19,537,242 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY FITNESS FIRST LUXEMBOURG S.C.A., UP TO 17,038,233 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY IIG VENTURES INDIA FUND III LLC, UP TO 15,862,353 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY TATA DIGITAL PRIVATE LIMITED, UP TO 11,056,131 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY CHIRATAE TRUST REPRESENTED BY ITS TRUSTEE VISTRATA ITC (INDIA) LIMITED AND ACTING THROUGH ITS INVESTMENT MANAGER, NAIGAMA INVESTMENT MANAGER LLP, UP TO 9,915,315 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY SCHROEDERS CAPITAL PRIVATE EQUITY ASIA MAURITIUS IV LIMITED, UP TO 7,912,322 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY TWENTY NINE CAPITAL PARTNERS LIMITED PARTNERSHIP (ACTING AT ALL TIMES THROUGH ITS GENERAL PARTNER, TWENTY NINE CAPITAL PARTNERS (GENERAL PARTNER) LIMITED), UP TO 6,532,434 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY ACCEL INDIA V (MAURITIUS) LIMITED, UP TO 6,165,096 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY ACCEL INDIA IV (MAURITIUS) LIMITED, UP TO 16,021,780 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY MUKESH BANSAL, UP TO 16,212,631 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY BRUNO EDUARD RASCHLE, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY JAMES SHA, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY ASAF AVIDAN ANTONIR, UP TO 907,287 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY KARAN HARESH MOTWANI, UP TO 907,284 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY NEHA KARAN MOTWANI, UP TO 633,813 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY HRITHIK RAKESH ROSHAN, UP TO 610,000 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY GUL RAMCHAND ADVANI, UP TO 467,333 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY VILAS S DHAR, UP TO 211,245 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY MUKUL DEORAS, UP TO 138,016 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY VIJAY KUMAR TAPARIA, UP TO 49,849 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY SHRADDHA SHETH, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY PRASHANT SUDHAKAR MACHWE, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY NIKHIL KAKKAR (THE "INDIVIDUAL SELLING SHAREHOLDERS") COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS", AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE", AND TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A PRE-IPO PLACEMENT OF SPECIFIED SECURITIES AGGREGATING UP TO ₹1,900.00 MILLION, AS MAY BE PERMITTED UNDER THE APPLICABLE LAW, AT ITS DISCRETION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER, OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND THE PROSPECTUS AND DETAILS OF THE PRE-IPO PLACEMENT, IF ANY, SHALL BE REPORTED TO THE STOCK EXCHANGES WITHIN 24 HOURS OF SUCH TRANSACTIONS, IN ACCORDANCE WITH REGULATION 54 OF THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company in consultation with the BRLMs and each of the Selling Shareholders, may for reasons to be recorded in writing, extend the Bid Offer Period for a minimum of one Working Day, subject to the Bid Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and intimation to Self-Certified Syndicate Banks ("SCSBs"), the Designated Intermediaries (as defined hereinafter) and the Sponsor Banks, (as defined hereinafter) as applicable.

This is an Offer in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. This Offer is being made through the Book Building Process in compliance with Regulation 6(2) of the SEBI ICDR Regulations wherein in terms of Regulation 32(2) of the SEBI ICDR Regulations not less than 75% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") and such portion of the "QIB Portion" provided that our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"). 40% of the Anchor Investor Portion shall be reserved as follows: (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds and Life Insurance Companies and Pension Funds at or above the price at which Equity Shares will be allocated to Anchor Investors ("Anchor Investor Allocation Price") in accordance with the SEBI ICDR Regulations and any under-subscription of 6.67% of the Anchor Investor Portion reserved for Life Insurance Companies and Pension Funds, such under-subscription portion may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be allotted to QIBs, then the entire Bid Amount (as defined hereinafter) will be refunded forthwith. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Offer shall be available for allocation to NBIs of which (a) one third portion shall be reserved for Bidders with application size of more than ₹20 million and up to ₹1.00 million; and (b) two-thirds of the portion shall be reserved for Bidders with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to Bidders in other sub-category of the NBIs in accordance with SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, not more than 10% of the Offer shall be available for allocation to Retail Individual Bidders ("RIB") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts (including UPI ID (defined hereinafter) in case of UPI Bidders (defined hereinafter) using the UPI Mechanism (defined hereinafter)), in which case the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. For details, see "Offer Procedure" on page 536 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP, on July 7, 2026 with the Stock Exchanges and Securities and Exchange Board of India ("SEBI"). Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of publication of this public announcement by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e., BSE at www.bseindia.com and NSE at www.nseindia.com, on the website of the Company at www.cult.fit, and on the websites of the Book Running Lead Managers ("BRLMs") i.e., Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jeffries.com, www.jmfi.com and www.morganstanley.com, respectively. Our Company invites the public to give their comments on the DRHP filed with SEBI and the Stock Exchanges, with respect to disclosures made in the DRHP. The public is requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Offer on or before 5:00 p.m. on the 21st day from the date of publication of this public announcement in accordance with Regulation 26(2) of the SEBI ICDR Regulations.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" beginning on page 21 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when issued through the RHP, are proposed to be listed on the Stock Exchanges.

For details of the share capital and capital structure and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, please see the section titled "Capital Structure" on page 104 of the DRHP. The liability of the members of our Company is limited by their shares. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on page 298 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER	
Axis Capital Limited 1 st Floor, Axis House P.B. Marg Worli Mumbai - 400 025 Maharashtra, India Tel: +91 22 4325 2183 E-mail: cultfit ipo@axiscap.in Website: www.axiscapital.co.in Investor Grievance ID: complaints@axiscap.in Contact Person: Pavan Naik SEBI Registration Number: INM000012029	Goldman Sachs (India) Securities Private Limited 10 th Floor Ascent-Worli, Sudam Kulu Ahire Marg, Worli, Mumbai - 400 025 Maharashtra, India Tel: +91 22 6616 9000 E-mail: gs-cultfit@gs.com Website: www.goldmansachs.com Investor Grievance ID: india-client-support@gs.com Contact Person: Achint Parmarandarkar/Harsh Parekh SEBI Registration Number: INM000011054	Jefferies India Private Limited Level 16, Express Towers, Nariman Point, Mumbai - 400 021, Maharashtra, India Tel: +91 22 4356 6000 E-mail: Cultfit.PO@jefferies.com Website: www.jeffries.com Investor Grievance ID: jipl.grievance@jefferies.com Contact Person: Nidhi Rana, Vrini Menghrajani SEBI Registration Number: INM000011443	JM Financial Limited 7 th Floor, Energy, Appasaheb Marathe Marg, Prabhadevi Mumbai - 400 025 Maharashtra, India Tel: +91 22 6630 3030 E-mail: cultfit.ipo@jmfi.com Website: www.jmfi.com Investor grievance ID: grievance.india@jmfi.com Contact Person: Prachee Dhuri SEBI Registration No: INM000010361	Morgan Stanley India Company Private Limited Altimus, Level 39 & 40, Pandurang Burchkar Marg, Worli, Mumbai - 400 018 Maharashtra, India Tel: +91 22 6118 1000 E-mail: cultfitipo@morganstanley.com Website: www.morganstanley.com Investor Grievance ID: investors_india@morganstanley.com Contact Person: Aditi Herga SEBI Registration No: INM000011203	KFINTECH KFin Technologies Limited 301, The Centrum, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Kurla, Mumbai - 400 070, Maharashtra, India Tel: +91 40 6716 2222/180003094001 E-mail: cultfit.ipo@kfnitech.com Website: www.kfnitech.com Investor grievance e-mail: ehw@kfnitech.com Contact Person: M. Murali Krishna SEBI Registration No.: INR000002221

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

Place: Chennai
 Date: July 7, 2026

CULT.FIT LIMITED (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited) is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on July 7, 2026. The DRHP is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e., BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.cult.fit and on the websites of the BRLMs, i.e., Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jeffries.com, www.jmfi.com and www.morganstanley.com, respectively. Any potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" on page 21 of the DRHP. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, when filed, for making any investment decision.

This announcement is not for publication or distribution to persons in the United States. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act ("Rule 144A")) and referred to in the Draft Red Herring Prospectus as "QIBs", for the avoidance of doubt, the term U.S. QIBs does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the Draft Red Herring Prospectus as "QIBs" in one or more transactions exempt from the registration requirements of the U.S. Securities Act, and (ii) outside the United States in "offshore transactions", as defined in, and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.

For **CULT.FIT LIMITED**
 (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)
 On behalf of the Board of Directors
 Sd/-
Siddharth Sharma
 Company Secretary and Compliance Officer

Utkarsh Small Finance Bank
Aapki Ummeed Ka Khaata
 (A Scheduled Commercial Bank)
UTKARSH SMALL FINANCE BANK LIMITED
 CIN: L65992UP2016PLC082804
 Registered Office: Utkarsh Tower, NH - 31 (Airport Road), Sehmampur, Kazi Sarai, Harhua, Varanasi, Uttar Pradesh, PIN - 221105.
 Tel. No.: +91-542-6605555 | Email: shareholders@utkarsh.bank.in
 Website: www.utkarsh.bank.in

NOTICE IS HEREBY GIVEN THAT THE TENTH (10th) ANNUAL GENERAL MEETING ("AGM") OF THE MEMBERS OF UTKARSH SMALL FINANCE BANK LIMITED ("USFBL" OR "THE BANK") WILL BE HELD ON TUESDAY, AUGUST 04, 2026 AT 2.30 P.M., INDIAN STANDARD TIME ("IST") THROUGH VIDEO CONFERENCE ("VC") / OTHER AUDIO-VISUAL MEANS ("OAVM") TO TRANSACT THE BUSINESS AS SET OUT IN THE NOTICE OF THE AGM WHICH WILL BE CIRCULATED FOR CONVENING THE AGM.

1. This is in compliance with the applicable provisions of the Companies Act, 2013 and the Rules made thereunder and Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") read with the Ministry of Corporate Affairs, Government of India ("MCA") Circular No. 03/2025 dated September 22, 2025 (in continuation with the Circulars issued earlier in this regard ("MCA Circulars") and the SEBI wide various circulars issued in this regard ("SEBI Circulars") has permitted companies to hold AGM through VC or OAVM, without physical presence of the Members at a common venue.
2. The Notice of AGM and Annual Report of the Bank for the Financial Year 2025-26 will be sent electronically to those Members whose e-mail addresses are registered with the Bank/ Registrar and Transfer Agent ("RTA") i.e. KFin Technologies Limited ("KFIN") or with the Depository Participant ("DP"). The Bank shall send a physical copy of the Annual Report to those Members who request for the same at shareholders@utkarsh.bank.in mentioning their DP ID and Client ID.
3. All the shares of the Bank are Dematerialized form. Members holding shares in Dematerialized form and who have not registered/updated their e-mail addresses with the Depository Participants are requested to register/update their e-mail addresses and mobile numbers with their DP by following procedures prescribed by their DP.
4. The Bank has engaged the services of National Securities Depository Limited ("NSDL") for the purpose of providing e-voting facility to its Members to cast their votes on all resolutions set out in the Notice of 10th AGM. The details such as manner of (i) registering/updated email addresses, (ii) casting vote through remote e-voting/e-voting during the AGM and (iii) attending the AGM through VC/OAVM will be set out in the Notice of the AGM, which will be circulated through e-mail. The remote e-voting facility would be available during the following period:

Commencement of e-Voting	Saturday, August 01, 2026 at 9:00 a.m. (IST)
End of e-Voting	Monday, August 03, 2026 at 5:00 p.m. (IST)

5. The Members are requested to carefully read all the Notes set out in the Notice of 10th AGM (being sent electronically) and particulars, instructions for joining AGM and manner of casting vote through remote e-voting or e-voting at the AGM.
6. The Notice of 10th AGM and the Annual Report for Financial Year 2025-26 will also be made available on the Bank's website www.utkarsh.bank.in and websites of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and also on the website of NSDL at www.evoting.nsdl.com

For Utkarsh Small Finance Bank Limited
 Sd/-
Muthiah Ganapathy
 Company Secretary & Compliance Officer

Date: July 08, 2026
 Place: Mumbai

CONCORD BIOTECH
Biotech for Mankind..

CONCORD BIOTECH LIMITED
 CIN : L24230GJ1984PLC007440
 Regd. Off.: 1482-86, Trasad Road, Dhoka, Ahmedabad-382225, Gujarat, India
 Tel. No. : + 91-79-68138725 | Email : compliance@concordbiotech.com
 Website : https://www.concordbiotech.com

NOTICE OF THE 41ST ANNUAL GENERAL MEETING, BOOK CLOSURE AND REMOTE E-VOTING INFORMATION

Notice is hereby given that the 41st Annual General Meeting ("AGM") of the Members of the Company will be held on **Friday, July 31, 2026 at 12:00 Noon** through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the business as set out in the Notice of AGM. The Company has sent the Annual Report along with Notice convening 41st AGM on Tuesday, July 07, 2026, through electronic mode to all the Members whose e-mail IDs are registered with the Company's Registrar & Share Transfer Agent, M/s MUFG Intime India Private Limited / Depository Participant(s). In accordance with the provisions of the Companies Act, 2013 ("the Act"), read with the Rules made thereunder and General Circular Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 5, 2020 and subsequent circulars issued in this regard, the latest being 03/2025 dated September 22, 2025, collectively referred to as "MCA Circulars", and other applicable circulars issued by the Securities and Exchange Board of India (SEBI) including Circular No. SEBI/HO/CFD/CFD-PO-D-2/P/CIR/2024/133 dated October 3, 2024 ("SEBI Circulars"), AGM of the Company is being held through VC / OAVM.

In accordance with the aforesaid Circulars, Notice of AGM along with the Annual Report 2025-26 has been sent only by electronic mode to those Members whose e-mail addresses are registered with the Company/ Depositories. The Company has also sent a letter containing the web-link along with the path to access the Annual Report 2025-26 (including the Notice) to the Members whose email addresses are not registered with the Company/ RTA/ Depository Participant(s) pursuant to Regulation 36(1)(b) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (Listing Regulations). Members may note that the Notice of AGM and Annual Report 2025-26 is also available at the Company's website i.e. www.concordbiotech.com, website of Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and on the website of the Central Depository Services (India) Limited (agency providing remote e-voting facility and e-voting facility during the AGM) i.e. www.evotingindia.com. Members can attend and participate in the AGM through the VC / OAVM facility only. The instructions for joining the AGM are provided in the Notice of the AGM. Members attending the meeting through VC / OAVM shall be counted for the purpose of reckoning the quorum as per Section 103 of the Companies Act, 2013.

Notice is also hereby given that pursuant to Regulation 42 of Listing Regulations, the Company has fixed record date as Friday, July 24, 2026 for the purpose of identification of shareholders to whom dividend is to be paid and for the purpose of 41st AGM of the Company. Pursuant to the provisions of Section 108 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended and Regulation 44 of the Listing Regulations, members are provided with the facility to cast their vote electronically through remote e-voting or e-voting during the AGM services provided by the Central Depository Services (India) Limited on all resolutions as set forth in the 41st AGM Notice. The voting rights of the members shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as on Friday, July 24, 2026 ("cut-off date").

The remote e-voting period commences on Tuesday, July 28, 2026 [09:00 A.M. IST] and ends on Thursday, July 30, 2026 [05:00 P.M. IST]. During this period, the Members may cast their vote electronically. The remote e-voting module shall be disabled by the Central Depository Services (India) Limited thereafter. Those Members, who shall be present in the AGM through VC/OAVM facility and had not cast their votes on the Resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.

The members who have cast their votes by remote e-voting prior to the AGM may also attend/ participate in the AGM through VC/OAVM but shall not be entitled to cast their votes again.

Any person, who acquires shares of the Company and becomes a Member of the Company after the Notice has been sent electronically by the Company and holds shares as on the cut-off date, may obtain the log in ID and password by sending a request to helpdesk@concordbiotech.com. However, if he/she is already registered with CDSL for remote e-voting, then he/she can use his/her existing User ID and password for casting the votes. The manner of remote e-voting and voting at the AGM by members holding shares in dematerialized mode, physical mode and process to register e-mail addresses for members who have not registered their email addresses is provided in the Notice of the 41st AGM.

In case Member(s) have not registered their e-mail addresses with the Company/ Depository, please follow the below instructions to register e-mail address for obtaining Annual Report and login details for e-voting - Members holding shares in Demat mode can get their E-mail ID registered by contacting their respective Depository Participant or by e-mail to complianceofficer@concordbiotech.com

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at toll free no. 18002109911.

For, **CONCORD BIOTECH LIMITED**
 Sd/- **Paritosh Trivedi**
 Company Secretary & Compliance Officer (ACS : 63623)

Place : Ahmedabad
 Date : July 07, 2026

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES OR UNITS NOR IS IT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES OF CULT.FIT LIMITED (FORMERLY CULT.FIT PRIVATE LIMITED AND CUREFIT HEALTHCARE PRIVATE LIMITED) ON THE MAIN BOARD OF BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES", IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT



(Please scan this QR code to view the Draft Red Herring Prospectus)



CULT.FIT LIMITED

(Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)

Our Company was originally incorporated as 'Cure Fit Healthcare Private Limited' as a private limited company under the Companies Act, 2013, at Bengaluru, Karnataka, pursuant to a certificate of incorporation dated May 24, 2016 issued by the Registrar of Companies, Central Registration Centre ("CRC"). Subsequently, the name of the Company changed to 'CureFit Healthcare Private Limited' pursuant to a Board resolution dated September 22, 2016 and special resolution passed by the Shareholders dated September 23, 2016 on account of re-branding 'CureFit' for branding and marketing purposes, and a fresh certificate of incorporation dated November 16, 2016 issued by the Registrar of Companies, Karnataka at Bengaluru. Further, the name of the Company changed to 'Cult.Fit Private Limited' pursuant to a Board resolution dated March 3, 2025 and special resolution passed by the Shareholders dated March 13, 2026 on account of re-branding 'Cult.Fit' to reflect our Company's business identity and branding strategy, and a fresh certificate of incorporation dated April 29, 2026 issued by the Registrar of Companies, Central Processing Centre ("CPC"). Our Company was thereafter converted into a public limited company pursuant to a resolution passed by our Board on June 16, 2026 and resolution passed by our Shareholders on June 17, 2026 and the name of our Company changed to 'Cult.Fit Limited'. A fresh certificate of incorporation dated June 25, 2026 was issued by the CPC pursuant to conversion to a public limited company. For further details, including details in relation to the changes in the registered office of our Company, see "History and Certain Corporate Matters - Changes in our Registered Office" on page 298 of the draft red herring prospectus dated July 6, 2026 ("DRHP").

Corporate Identity Number: U74999TN2016PLC176669

Registered Office: 3rd Floor, Plot No. 269, Sy. No. 439/1B, Rajiv Gandhi Road, Chennai, Sholinganallur, Saidapet, Kanchipuram - 600 119, Tamil Nadu, India
 Corporate Office: Curefit HQ, 17/17C - BDA, 18th Cross, Sector-3, HSR Layout, Bengaluru, - 560 102, Karnataka
 Tel: +91 9187219016, Website: www.cult.fit, Contact person: Siddharth Sharma, Company Secretary and Compliance Officer, E-mail: secretarial@cult.fit

OUR COMPANY IS A PROFESSIONALLY MANAGED COMPANY AND DOES NOT HAVE AN IDENTIFIABLE PROMOTER

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF CULT.FIT LIMITED ("OUR COMPANY" OR "THE COMPANY") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹9,500.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 178,609,200 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS CONSISTING OF UP TO 24,664,113 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MACRITICHE INVESTMENTS PTE. LTD., UP TO 486,589 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY FITNESS FIRST LUXEMBOURG S.C.A., UP TO 17,038,233 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY IDG VENTURES INDIA FUND III LLC, UP TO 15,862,353 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY TATA DIGITAL PRIVATE LIMITED, UP TO 11,056,131 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY CHIRATAE TRUST REPRESENTED BY ITS TRUSTEE VISTRA ITCL (INDIA) LIMITED AND ACTING THROUGH ITS INVESTMENT MANAGER, NAIGAMA INVESTMENT MANAGER LLP, UP TO 9,915,315 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SCHRODERS CAPITAL PRIVATE EQUITY ASIA MAURITIUS IV LIMITED, UP TO 7,912,322 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY TWENTY NINE CAPITAL PARTNERS LIMITED PARTNERSHIP (ACTING AT ALL TIMES THROUGH ITS GENERAL PARTNER, TWENTY NINE CAPITAL PARTNERS (GENERAL PARTNER) LIMITED), UP TO 6,532,434 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ACCEL INDIA V (MAURITIUS) LIMITED, UP TO 6,165,099 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ACCEL INDIA IV (MAURITIUS) LIMITED, UP TO 5,222,078 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY EPIO CAPITAL B. LP., UP TO 4,130,615 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY KALAARI CAPITAL PARTNERS III, L.L.C., UP TO 3,278,461 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY KALAARI CAPITAL PARTNERS OPPORTUNITY FUND, L.L.C., UP TO 2,315,969 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VALECHA INVESTMENTS PRIVATE LIMITED, UP TO 1,160,568 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SATYADHARMA INVESTMENTS AND TRADING COMPANY PRIVATE LIMITED, UP TO 1,024,116 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY CASTLE INVESTMENT AND INDUSTRIES PRIVATE LIMITED, UP TO 941,781 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ANANTH SANKARANARAYANAN FAMILY TRUST, UP TO 816,081 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SUN N SAND HOTELS PRIVATE LIMITED, UP TO 729,958 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VENKTESH INVESTMENT AND TRADING COMPANY PRIVATE LIMITED, UP TO 686,412 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ENDIYA SEED CO-CREATION FUND (A SCHEME OF ENDIYA TRUST, ACTING THROUGH ITS TRUSTEE, ENDIYA TRUSTEE PRIVATE LIMITED), UP TO 641,764 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY EXTREME BRANDS LLP, UP TO 486,589 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ONYX SHAREHOLDERS LLC, UP TO 363,085 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY DOLI TRADING AND INVESTMENTS PRIVATE LIMITED (THE "INVESTOR SELLING SHAREHOLDERS"), UP TO 16,021,780 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MUKESH BANSAL, UP TO 10,212,631 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY BRUNO EDUARD RASCHLE, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY JAMES SHA, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ASAF AVIDAN ANTONIK, UP TO 907,287 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY KARAN HARESH MOTWANI, UP TO 907,284 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY NEHA KARAN MOTWANI, UP TO 633,813 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY HRITHIK RAKESH ROSHAN, UP TO 610,000 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY GUL RAMCHAND ADVANI, UP TO 487,333 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VILAS S DHAR, UP TO 211,245 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MUKUL DEORAS, UP TO 138,016 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VIJAY KUMAR TAPARIA, UP TO 49,849 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SHRADDDHA SETHI, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY PRASHANT SUDHAKAR MACHWE, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY NIKHIL KAKKAR (THE "INDIVIDUAL SELLING SHAREHOLDERS") (COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS", AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE", AND TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

OUR COMPANY, IN CONSULTATION WITH THE BRLMs, MAY CONSIDER A PRE-IPO PLACEMENT OF SPECIFIED SECURITIES AGGREGATING UP TO ₹1,900.00 MILLION, AS MAY BE PERMITTED UNDER THE APPLICABLE LAW, AT ITS DISCRETION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMs. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER, OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND THE PROSPECTUS AND DETAILS OF THE PRE-IPO PLACEMENT, IF ANY, SHALL BE REPORTED TO THE STOCK EXCHANGES WITHIN 24 HOURS OF SUCH TRANSACTIONS, IN ACCORDANCE WITH REGULATION 34 OF THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid/ Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company in consultation with the BRLMs and each of the Selling Shareholders, may for reasons to be recorded in writing, extend the Bid/ Offer Period for a minimum of one Working Day, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and intimation to Self-Certified Syndicate Banks ("SCSBs"), the Designated Intermediaries (as defined hereinafter) and the Sponsor Banks, (as defined hereinafter) as applicable.

This is an Offer in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. This Offer is being made through the Book Building Process in compliance with Regulation 6(2) of the SEBI ICDR Regulations wherein in terms of Regulation 32(2) of the SEBI ICDR Regulations not less than 75% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") and such portion of the "QIB Portion" provided that our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"). 40% of the Anchor Investor Portion shall be reserved as follows: (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds and Life Insurance Companies and Pension Funds at or above the price at which Equity Shares will be allocated to Anchor Investors ("Anchor Investor Allocation Portion") in accordance with the SEBI ICDR Regulations and any under-subscription of 6.67% of the Anchor Investor Portion reserved for Life Insurance Companies and Pension Funds, such under-subscription portion may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be allotted to QIBs, then the entire Bid Amount (as defined hereinafter) will be refunded forthwith. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Offer shall be available for allocation to NBIs of which (a) one third portion shall be reserved for Bidders with application size of more than ₹0.20 million and up to ₹1.00 million; and (b) two-thirds of the portion shall be reserved for Bidders with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to Bidders in other sub-category of the NBIs in accordance with SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, not more than 10% of the Offer shall be available for allocation to Retail Individual Bidders ("RIB") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts (including UPI ID (defined hereinafter)) in case of UPI Bidders (defined hereinafter) using the UPI Mechanism (defined hereinafter), in which case the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. For details, see "Offer Procedure" on page 536 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP, on July 7, 2026 with the Stock Exchanges and Securities and Exchange Board of India ("SEBI"). Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of publication of this public announcement by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE at www.bseindia.com and NSE at www.nseindia.com, on the website of the Company at www.cult.fit; and on the websites of the Book Running Lead Managers ("BRLMs"), i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jefferies.com, www.jmfi.com and www.morganstanley.com, respectively. Our Company invites the public to give their comments on the DRHP filed with SEBI and the Stock Exchanges, with respect to disclosures made in the DRHP. The public is requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Offer on or before 5:00 p.m. on the 21st day from the date of publication of this public announcement in accordance with Regulation 26(2) of the SEBI ICDR Regulations.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" beginning on page 21 of the DRHP. Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when issued through the RHP, are proposed to be listed on the Stock Exchanges.

For details of the share capital and capital structure and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, please see the section titled "Capital Structure" on page 104 of the DRHP. The liability of the members of our Company is limited by their shares. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on page 298 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER	
AXIS CAPITAL	Goldman Sachs	Jefferies	JM Financial	Morgan Stanley	
Axis Capital Limited 1 st Floor, Axis House P.B. Marg, Worli Mumbai - 400 025 Maharashtra, India Tel: +91 22 4325 2183 E-mail: cultfit ipo@axiscap.in Website: www.axiscapital.co.in Investor Grievance ID: complaints@axiscap.in Contact Person: Pavan Naik SEBI Registration Number: INM000012029	Goldman Sachs (India) Securities Private Limited 10 th Floor Ascent-Worli, Sudam Kalu Anile Marg, Worli, Mumbai - 400 025 Maharashtra, India Tel: +91 22 8616 9000 E-mail: gs-cultfit@gs.com Website: www.goldmansachs.com Investor Grievance ID: india-client-support@gs.com Contact Person: Ashot Parmarandkar/ Harsh Parekh SEBI Registration Number: INM00011054	Jefferies India Private Limited Level 16, Express Towers, Nariman Point, Mumbai - 400 021, Maharashtra, India Tel: +91 22 4356 6000 E-mail: cultfit IPO@jefferies.com Website: www.jefferies.com Investor Grievance ID: jpl.grievance@jefferies.com Contact Person: Nidhi Rana, Viti Menghrajani SEBI Registration Number: INM00011443	JM Financial Limited 7 th Floor, Chenergy, Appasaheb Marathe Marg, Prabhadevi Mumbai - 400 025 Maharashtra, India Tel: +91 22 6630 3030 E-mail: cultfit ipo@jmfi.com Website: www.jmfi.com Investor grievance ID: grievance.bd@jmfi.com Contact Person: Prachee Dhuri SEBI Registration No: INM00010381	Morgan Stanley India Company Private Limited Allium, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai - 400 018 Maharashtra, India Tel: + 91 22 6118 1000 E-mail: cultfitipo@morganstanley.com Website: www.morganstanley.com Investor Grievance ID: investors_india@morganstanley.com Contact Person: Adith Herga SEBI Registration No: INM000011203	KFin Technologies Limited 301, The Centrum, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Kurla, Mumbai - 400 070, Maharashtra, India Tel: +91 40 6716 2222/18003094001 E-mail: cultfit_ipo@kfintech.com Website: www.kfintech.com Investor grievance e-mail: einward.ris@kfintech.com Contact Person: M. Murali Krishna SEBI Registration No.: INR00000221

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

Place: Chennai
 Date: July 7, 2026

CULT.FIT LIMITED (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited) is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on July 7, 2026. The DRHP is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.cult.fit; and on the websites of the BRLMs, i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jefferies.com, www.jmfi.com and www.morganstanley.com, respectively. Any potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" on page 21 of the DRHP. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, when filed, for making any investment decision.

This announcement is not for publication or distribution to persons in the United States. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act ("Rule 144A")) and referred to in the Draft Red Herring Prospectus as "U.S. QIBs"; for the avoidance of doubt, the term U.S. QIBs does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the Draft Red Herring Prospectus as "QIBs" in one or more transactions exempt from the registration requirements of the U.S. Securities Act; and (ii) outside the United States in "offshore transactions", as defined in, and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.

For **CULT.FIT LIMITED**
 (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)
 On behalf of the Board of Directors
 Sd/-
Siddharth Sharma
 Company Secretary and Compliance Officer

Utkarsh Small Finance Bank
Aapki Ummeed Ka Khaata
 (A Scheduled Commercial Bank)
UTKARSH SMALL FINANCE BANK LIMITED
 CIN: L65992UP2016PLC082804
 Registered Office: Utkarsh Tower, NH - 31 (Airport Road), Sehmalpur, Kazi Sarai, Harhua, Varanasi, Uttar Pradesh, PIN - 221105.
 Tel. No.: +91-542-6605555 | Email: shareholders@utkarsh.bank.in
 Website: www.utkarsh.bank.in

NOTICE IS HEREBY GIVEN THAT THE TENTH (10th) ANNUAL GENERAL MEETING ("AGM") OF THE MEMBERS OF UTKARSH SMALL FINANCE BANK LIMITED ("USFB" OR "THE BANK") WILL BE HELD ON TUESDAY, AUGUST 04, 2026 AT 2.30 P.M., INDIAN STANDARD TIME ("IST") THROUGH VIDEO CONFERENCE ("VC") / OTHER AUDIO-VISUAL MEANS ("OAVM") TO TRANSACT THE BUSINESS AS SET OUT IN THE NOTICE OF THE AGM WHICH WILL BE CIRCULATED FOR CONVENING THE AGM.

- This is in compliance with the applicable provisions of the Companies Act, 2013 and the Rules made thereunder and Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") read with the Ministry of Corporate Affairs, Government of India ("MCA") Circular No. 03/2025 dated September 22, 2025 (in continuation with the Circulars issued earlier in this regard) ("MCA Circulars") and the SEBI vide various circulars issued in this regard ("SEBI Circulars") has permitted companies to hold AGM through VC or OAVM, without physical presence of the Members at a common venue.
 - The Notice of AGM and Annual Report of the Bank for the Financial Year 2025-26 will be sent electronically to those Members whose e-mail addresses are registered with the Bank/ Registrar and Transfer Agent ("RTA") i.e. KFin Technologies Limited ("KFIN") or with the Depository Participant ("DP"). The Bank shall send a physical copy of the Annual Report to those Members who request for the same at shareholders@utkarsh.bank.in mentioning their DP ID and Client ID.
 - All the shares of the Bank are Dematerialized form. Members holding shares in Dematerialized form and who have not registered/updated their e-mail addresses with the Depository Participants are requested to register/update their e-mail addresses and mobile numbers with their DP by following procedures prescribed by their DP.
 - The Bank has engaged the services of National Securities Depository Limited ("NSDL") for the purpose of providing e-voting facility to its Members to cast their votes on all resolutions set out in the Notice of 10th AGM. The details such as manner of (i) registering/updating email addresses, (ii) casting vote through remote e-voting/e-voting during the AGM and (iii) attending the AGM through VC/OAVM will be set out in the Notice of the AGM, which will be circulated through e-mail. The remote e-Voting facility would be available during the following period:
- | | |
|--------------------------|--|
| Commencement of e-Voting | Saturday, August 01, 2026 at 9:00 a.m. (IST) |
| End of e-Voting | Monday, August 03, 2026 at 5:00 p.m. (IST) |
- The Members are requested to carefully read all the Notes set out in the Notice of 10th AGM (being sent electronically) and particulars, instructions for joining AGM and manner of casting vote through remote e-voting or e-voting at the AGM.
 - The Notice of 10th AGM and the Annual Report for Financial Year 2025-26 will also be made available on the Bank's website www.utkarsh.bank.in and websites of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and also on the website of NSDL at www.evoting.nsdl.com
- For Utkarsh Small Finance Bank Limited
 Sd/-
Muthiah Ganapathy
 Company Secretary & Compliance Officer
- Date: July 08, 2026
 Place: Mumbai

CONCORD BIOTECH
Biotech for Mankind...
CONCORD BIOTECH LIMITED
 CIN : L24230GJ1984PLC007440
 Regd. Off.: 1482-86, Trasad Road, Dholka, Ahmedabad - 382225, Gujarat, India
 Tel. No.: +91-79-88138725 | Email: compliance@concordbiotech.com
 Website: https://www.concordbiotech.com

NOTICE OF THE 41ST ANNUAL GENERAL MEETING, BOOK CLOSURE AND REMOTE E-VOTING INFORMATION

Notice is hereby given that the 41st Annual General Meeting ("AGM") of the Members of the Company will be held on **Friday, July 31, 2026 at 12:00 Noon** through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the business as set out in the Notice of AGM.

The Company has sent the Annual Report along with Notice convening 41st AGM on Tuesday, July 07, 2026, through electronic mode to all the Members whose e-mail IDs are registered with the Company's Registrar & Share Transfer Agent, M/s MUFG Intime India Private Limited / Depository Participant(s).

In accordance with the provisions of the Companies Act, 2013 ("the Act"), read with the Rules made thereunder and General Circular Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 5, 2020 and subsequent circulars issued in this regard, the latest being 03/2025 dated September 22, 2025, collectively referred to as "MCA Circulars", and other applicable circulars issued by the Securities and Exchange Board of India (SEBI) including Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024 ("SEBI Circulars"). AGM of the Company is being held through VC / OAVM.

In accordance with the aforesaid Circulars, Notice of AGM along with the Annual Report 2025-26 has been sent only by electronic mode to those Members whose e-mail addresses are registered with the Company/ Depositories. The Company has also sent a letter containing the web-link along with the path to access the Annual Report 2025-26 (including the Notice) to the Members whose email addresses are not registered with the Company/ RTA/ Depository Participant(s) pursuant to Regulation 38(1)(b) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (Listing Regulations). Members may note that the Notice of AGM and Annual Report 2025-26 is also available at the Company's website i.e., www.concordbiotech.com, website of Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and on the website of the Central Depository Services (India) Limited (agency providing remote e-voting facility and e-voting facility during the AGM) i.e., www.evotingindia.com. Members can attend and participate in the AGM through the VC / OAVM facility only. The instructions for joining the AGM are provided in the Notice of the AGM. Members attending the meeting through VC / OAVM shall be counted for the purpose of reckoning the quorum as per Section 103 of the Companies Act, 2013.

Notice is also hereby given that pursuant to Regulation 42 of Listing Regulations, the Company has fixed record date as Friday, July 24, 2026 for the purpose of identification of shareholders to whom dividend is to be paid and for the purpose of 41st AGM of the Company. Pursuant to the provisions of Section 108 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended and Regulation 44 of the Listing Regulations, members are provided with the facility to cast their vote electronically through remote e-voting as e-voting during the AGM services provided by the Central Depository Services (India) Limited on all resolutions as set forth in the 41st AGM Notice. The voting rights of the members shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as on Friday, July 24, 2026 ("cut-off date").

The remote e-voting period commences on Tuesday, July 28, 2026 (09:00 A.M. IST) and ends on Thursday, July 30, 2026 (05:00 P.M. IST). During this period, the Members may cast their vote electronically. The remote e-voting module shall be disabled by the Central Depository Services (India) Limited thereafter. Those Members, who shall be present in the AGM through VC/OAVM facility and had not cast their votes on the Resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.

The members who have cast their votes by remote e-voting prior to the AGM may also attend/participate in the AGM through VC/OAVM but shall not be entitled to cast their votes again.

Any person, who acquires shares of the Company and becomes a Member of the Company after the Notice has been sent electronically by the Company and holds shares as on the cut-off date, may obtain the log in ID and password by sending a request to helpdesk.helpdesk.evoting@cdsindia.com. However, if he/she is already registered with CDSL for remote e-voting, then he/she can use his/ her existing User ID and password for casting the votes.

The manner of remote e-voting and voting at the AGM by members holding shares in dematerialized mode, physical mode and process to register e-mail addresses for members who have not registered their email addresses is provided in the Notice of the 41st AGM.

In case Member(s) have not registered their e-mail addresses with the Company/ Depository, please follow the below instructions to register e-mail address for obtaining Annual Report and login details for e-voting - Members holding shares in Demat mode can get their E-mail ID registered by contacting their respective Depository Participant or by e-mail to complianceofficer@concordbiotech.com


If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting system, you can write an email to helpdesk.evoting@cdsindia.com or contact at toll free no. 18002109911.

For **CONCORD BIOTECH LIMITED**
 Sd/- **Paritosh Trivedi**
 Company Secretary &
 Compliance Officer (ACS : 63623)

Place : Ahmedabad
 Date : July 07, 2026

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES OR UNITS NOR IS IT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA, INITIAL PUBLIC OFFERING OF EQUITY SHARES OF CULT.FIT LIMITED (FORMERLY CULT.FIT PRIVATE LIMITED AND CUREFIT HEALTHCARE PRIVATE LIMITED) ON THE MAIN BOARD OF BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES" IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT



CULT.FIT LIMITED

(Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)

Our Company was originally incorporated as "Cure Fit Healthcare Private Limited" as a private limited company under the Companies Act, 2013, at Bengaluru, Karnataka, pursuant to a certificate of incorporation dated May 24, 2016 issued by the Registrar of Companies, Central Registration Centre ("CRC"). Subsequently, the name of the Company changed to "CureFit Healthcare Private Limited" pursuant to a Board resolution dated September 22, 2016 and special resolution passed by the Shareholders dated September 23, 2016 on account of re-branding "CureFit" for branding and marketing purposes, and a fresh certificate of incorporation dated November 16, 2016 issued by the Registrar of Companies, Karnataka at Bengaluru. Further, the name of the Company changed to "Cult.Fit Private Limited" pursuant to a Board resolution dated March 3, 2026 and special resolution passed by the Shareholders dated March 13, 2026 on account of re-branding "Cult.Fit" to reflect our Company's business identity and branding strategy, and a fresh certificate of incorporation dated April 29, 2026 issued by the Registrar of Companies, Central Processing Centre ("CPC"). Our Company was thereafter converted into a public limited company pursuant to a resolution passed by our Board on June 16, 2026 and resolution passed by our Shareholders on June 17, 2026 and the name of our Company changed to "Cult.Fit Limited". A fresh certificate of incorporation dated June 25, 2026 was issued by the CPC pursuant to conversion to a public limited company. For further details, including details in relation to the changes in the registered office of our Company, see "History and Certain Corporate Matters - Changes in our Registered Office" on page 298 of the draft red herring prospectus dated July 6, 2026 ("DRHP").

Corporate Identity Number: U74989TN2016PLC176669
 Registered Office: 3rd Floor, Plot No. 269, Sy. No. 439/1B, Rajiv Gandhi Road, Chennai, Sholinganallur, Saidapet, Kanchipuram - 600 119, Tamil Nadu, India
 Corporate Office: CureFit HQ, 17/17C - BDA, 18th Cross, Sector-3, HSR Layout, Bengaluru, - 560 102, Karnataka
 Tel: +91 9187219018; Website: www.cult.fit; Contact person: Siddharth Sharma, Company Secretary and Compliance Officer; E-mail: secretnal@cult.fit

OUR COMPANY IS A PROFESSIONAL MANAGED COMPANY AND DOES NOT HAVE AN IDENTIFIABLE PROMOTER

INITIAL PUBLIC OFFERING OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF CULT.FIT LIMITED ("OUR COMPANY" OR "THE COMPANY") FOR CASH AT A PRICE OF ₹[•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[•] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[•] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹9,500.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 178,609,200 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS CONSISTING OF UP TO 24,664,113 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY MACRITCHE INVESTMENTS PTE. LTD., UP TO 19,537,242 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY FITNESS FIRST LUXEMBOURG S.C.A., UP TO 17,038,233 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY IIG VENTURES INDIA FUND III LLC, UP TO 15,862,353 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY TATA DIGITAL PRIVATE LIMITED, UP TO 11,856,131 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY CHIRATAE TRUST REPRESENTED BY ITS TRUSTEE VISTRAL ITC (INDIA) LIMITED AND ACTING THROUGH ITS INVESTMENT MANAGER, NAIGAMA INVESTMENT MANAGER LLP, UP TO 9,915,315 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY SCHROEDERS CAPITAL PRIVATE EQUITY ASIA MAURITIUS IV LIMITED, UP TO 7,912,322 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY TWENTY NINE CAPITAL PARTNERS LIMITED PARTNERSHIP (ACTING AT ALL TIMES THROUGH ITS GENERAL PARTNER, TWENTY NINE CAPITAL PARTNERS (GENERAL PARTNER) LIMITED), UP TO 6,532,434 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY ACCEL INDIA V (MAURITIUS) LIMITED, UP TO 6,165,096 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY ACCEL INDIA IV (MAURITIUS) LIMITED, UP TO 16,021,780 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY MUKESH BANSAI, UP TO 16,212,631 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY BRUNO EDUARD RASCHLE, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY JAMES SHA, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY ASAF AVIDAN ANTONIR, UP TO 907,287 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY KARAN HARESH MOTWANI, UP TO 907,284 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY NEHA KARAN MOTWANI, UP TO 633,813 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY HRITHIK RAKESH ROSHAN, UP TO 610,000 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY GUL RAMCHAND ADVANI, UP TO 467,335 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY VILAS S DHAR, UP TO 211,245 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY MUKUL DEORAS, UP TO 138,816 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY VIJAY KUMAR TAPARIA, UP TO 49,849 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY SHRADDHA SHETH, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY PRASHANT SUDHAKAR MACHWE, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY NIKHIL KAKKAR (THE "INDIVIDUAL SELLING SHAREHOLDERS") COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS", AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE", AND TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A PRE-IPO PLACEMENT OF SPECIFIED SECURITIES AGGREGATING UP TO ₹1,900.00 MILLION, AS MAY BE PERMITTED UNDER THE APPLICABLE LAW, AT ITS DISCRETION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER, OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND THE PROSPECTUS AND DETAILS OF THE PRE-IPO PLACEMENT, IF ANY, SHALL BE REPORTED TO THE STOCK EXCHANGES WITHIN 24 HOURS OF SUCH TRANSACTIONS, IN ACCORDANCE WITH REGULATION 54 OF THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company in consultation with the BRLMs and each of the Selling Shareholders, may for reasons to be recorded in writing, extend the Bid Offer Period for a minimum of one Working Day, subject to the Bid Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and intimation to Self-Certified Syndicate Banks ("SCSBs"), the Designated Intermediaries (as defined hereinafter) and the Sponsor Banks, (as defined hereinafter) as applicable.

This is an Offer in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. This Offer is being made through the Book Building Process in compliance with Regulation 6(2) of the SEBI ICDR Regulations wherein in terms of Regulation 32(2) of the SEBI ICDR Regulations not less than 75% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") and such portion of the "QIB Portion" provided that our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"). 40% of the Anchor Investor Portion shall be reserved as follows: (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds and Life Insurance Companies and Pension Funds at or above the price at which Equity Shares will be allocated to Anchor Investors ("Anchor Investor Allocation Price") in accordance with the SEBI ICDR Regulations and any under-subscription of 6.67% of the Anchor Investor Portion reserved for Life Insurance Companies and Pension Funds, such under-subscribed portion may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be allotted to QIBs, then the entire Bid Amount (as defined hereinafter) will be refunded forthwith. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Offer shall be available for allocation to NBIs of which (a) one third portion shall be reserved for Bidders with application size of more than ₹20 million and up to ₹1.00 million; and (b) two-thirds of the portion shall be reserved for Bidders with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to Bidders in other sub-category of the NBIs in accordance with SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, not more than 10% of the Offer shall be available for allocation to Retail Individual Bidders ("RIB") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts (including UPI ID (defined hereinafter) in case of UPI Bidders (defined hereinafter) using the UPI Mechanism (defined hereinafter)), in which case the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable to participate in the Offer. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" on page 536 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP, on July 7, 2026 with the Stock Exchanges and Securities and Exchange Board of India ("SEBI"). Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of publication of this public announcement by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE at www.bseindia.com and NSE at www.nseindia.com, on the website of the Company at www.cult.fit, and on the websites of the Book Running Lead Managers ("BRLMs"), i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jeffries.com, www.mfi.com and www.morganstanley.com, respectively. Our Company invites the public to give their comments on the DRHP filed with SEBI and the Stock Exchanges, with respect to disclosures made in the DRHP. The public is requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Offer on or before 5:00 p.m. on the 21st day from the date of publication of this public announcement in accordance with Regulation 26(2) of the SEBI ICDR Regulations.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" beginning on page 21 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when issued through the RHP, are proposed to be listed on the Stock Exchanges.

For details of the share capital and capital structure and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, please see the section titled "Capital Structure" on page 104 of the DRHP. The liability of the members of our Company is limited by their shares. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on page 298 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER	
Axis Capital Limited 1 st Floor, Axis House P.B. Marg Worli Mumbai - 400 025 Maharashtra, India Tel: +91 22 4325 2183 E-mail: cultfit ipo@axiscap.in Website: www.axiscapital.co.in Investor Grievance ID: complaints@axiscap.in Contact Person: Pavan Naik SEBI Registration Number: INM000012029	Goldman Sachs (India) Securities Private Limited 10 th Floor Ascent-Worli, Sudam Kulu Ahire Marg, Worli, Mumbai - 400 025 Maharashtra, India Tel: +91 22 6616 9000 E-mail: gs-cultfit@gs.com Website: www.goldmansachs.com Investor Grievance ID: india-client-support@gs.com Contact Person: Achint Parmarandak/Harsh Parekh SEBI Registration Number: INM000011054	Jefferies India Private Limited Level 16, Express Towers, Nariman Point, Mumbai - 400 021, Maharashtra, India Tel: +91 22 4356 6000 E-mail: Cultfit.IPO@jefferies.com Website: www.jeffries.com Investor Grievance ID: jipl.grievance@jefferies.com Contact Person: Nidhi Rana, Vrini Manghajsani SEBI Registration Number: INM000011443	JM Financial Limited 7 th Floor, Energy, Appasaheb Marathe Marg, Prabhadevi Mumbai - 400 025 Maharashtra, India Tel: +91 22 6630 3030 E-mail: cultfit.ipo@jmf.com Website: www.jmf.com Investor grievance ID: grievance.ipo@jmf.com Contact Person: Prachee Dhuri SEBI Registration No: INM000010361	Morgan Stanley India Company Private Limited Altimus, Level 39 & 40, Pandurang Burchkar Marg, Worli, Mumbai - 400 018 Maharashtra, India Tel: +91 22 6118 1000 E-mail: cultfitipo@morganstanley.com Website: www.morganstanley.com Investor Grievance ID: investors_india@morganstanley.com Contact Person: Aditi Heega SEBI Registration No: INM000011203	KFINTECH KFin Technologies Limited 301, The Centrum, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Kurla, Mumbai - 400 070, Maharashtra, India Tel: +91 40 6716 2222/180003094001 E-mail: cultfit.ipo@kfintech.com Website: www.kfintech.com Investor grievance e-mail: einwardns@kfintech.com Contact Person: M. Murali Krishna SEBI Registration No.: INR030000221

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For **CULT.FIT LIMITED**
 (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)
 On behalf of the Board of Directors
 Sd/-
Siddharth Sharma
 Company Secretary and Compliance Officer

CULT.FIT LIMITED (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited) is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on July 7, 2026. The DRHP is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.cult.fit; and on the websites of the BRLMs, i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jeffries.com, www.jmf.com and www.morganstanley.com, respectively. Any potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" on page 21 of the DRHP. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, when filed, for making any investment decision.

This announcement is not for publication or distribution to persons in the United States. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares in the Offer are being offered and sold (i) within the United States to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act ("Rule 144A")) and referred to in the Draft Red Herring Prospectus as "U.S. QIBs"; for the avoidance of doubt, the term U.S. QIBs does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the Draft Red Herring Prospectus as "QIBs" in one or more transactions exempt from the registration requirements of the U.S. Securities Act, and (ii) outside the United States in "offshore transactions", as defined in, and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.



Utkarsh Small Finance Bank
Aapki Ummeed Ka Khaata
 (A Scheduled Commercial Bank)
UTKARSH SMALL FINANCE BANK LIMITED
 CIN: L65992UP2016PLC082804
 Registered Office: Utkarsh Tower, NH - 31 (Airport Road), Sehmalpur, Kazi Sarai, Harhua, Varanasi, Uttar Pradesh, PIN - 221105.
 Tel. No.: +91-542-6605555 | Email: shareholders@utkarsh.bank.in
 Website: www.utkarsh.bank.in

NOTICE IS HEREBY GIVEN THAT THE TENTH (10th) ANNUAL GENERAL MEETING ("AGM") OF THE MEMBERS OF UTKARSH SMALL FINANCE BANK LIMITED ("USFB" OR "THE BANK") WILL BE HELD ON TUESDAY, AUGUST 04, 2026 AT 2.30 P.M., INDIAN STANDARD TIME ("IST") THROUGH VIDEO CONFERENCE ("VC") / OTHER AUDIO-VISUAL MEANS ("OAVM") TO TRANSACT THE BUSINESS AS SET OUT IN THE NOTICE OF THE AGM WHICH WILL BE CIRCULATED FOR CONVENING THE AGM.

- This is in compliance with the applicable provisions of the Companies Act, 2013 and the Rules made thereunder and Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") read with the Ministry of Corporate Affairs, Government of India ("MCA") Circular No. 03/2025 dated September 22, 2025 (in continuation with the Circulars issued earlier in this regard) ("MCA Circulars") and the SEBI vide various circulars issued in this regard ("SEBI Circulars") has permitted companies to hold AGM through VC or OAVM, without physical presence of the Members at a common venue.
- The Notice of AGM and Annual Report of the Bank for the Financial Year 2025-26 will be sent electronically to those Members whose e-mail addresses are registered with the Bank/ Registrar and Transfer Agent ("RTA") i.e. KFin Technologies Limited ("KFIN") or with the Depository Participant ("DP"). The Bank shall send a physical copy of the Annual Report to those Members who request for the same at shareholders@utkarsh.bank.in mentioning their DP ID and Client ID.
- All the shares of the Bank are Dematerialized form. Members holding shares in Dematerialized form and who have not registered/updated their e-mail addresses with the Depository Participants are requested to register/update their e-mail addresses and mobile numbers with their DP by following procedures prescribed by their DP.
- The Bank has engaged the services of National Securities Depository Limited ("NSDL") for the purpose of providing e-voting facility to its Members to cast their votes on all resolutions set out in the Notice of 10th AGM. The details such as manner of (i) registering/updating email addresses, (ii) casting vote through remote e-voting/e-voting during the AGM and (iii) attending the AGM through VC/OAVM will be set out in the Notice of the AGM, which will be circulated through e-mail. The remote e-Voting facility would be available during the following period:

Commencement of e-Voting	Saturday, August 01, 2026 at 9:00 a.m. (IST)
End of e-Voting	Monday, August 03, 2026 at 5:00 p.m. (IST)

For Utkarsh Small Finance Bank Limited
 Sd/-
Muthiah Ganapathy
 Company Secretary & Compliance Officer
 Date: July 08, 2026
 Place: Mumbai

CONCORD BIOTECH
Biotech for Mankind...
CONCORD BIOTECH LIMITED
 CIN : L24230GJ1984PLC007440
 Regd. Off.: 1482-86, Trasad Road, Dholka, Ahmedabad - 382225, Gujarat, India
 Tel. No.: +91-79-68138725 | Email: compliance@concordbiotech.com
 Website: https://www.concordbiotech.com

NOTICE OF THE 41ST ANNUAL GENERAL MEETING, BOOK CLOSURE AND REMOTE E-VOTING INFORMATION

Notice is hereby given that the 41st Annual General Meeting ("AGM") of the Members of the Company will be held on **Friday, July 31, 2026 at 12:00 Noon** through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the business as set out in the Notice of AGM. The Company has sent the Annual Report along with Notice convening 41st AGM on Tuesday, July 07, 2026, through electronic mode to all the Members whose e-mail IDs are registered with the Company's Registrar & Share Transfer Agent, M/s MUFG Intime India Private Limited / Depository Participant(s). In accordance with the provisions of the Companies Act, 2013 ("the Act"), read with the Rules made thereunder and General Circular Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 5, 2020 and subsequent circulars issued in this regard, the latest being 03/2025 dated September 22, 2025, collectively referred to as "MCA Circulars", and other applicable circulars issued by the Securities and Exchange Board of India (SEBI) including Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024 ("SEBI Circulars"). AGM of the Company is being held through VC / OAVM.

In accordance with the aforesaid Circulars, Notice of AGM along with the Annual Report 2025-26 has been sent only by electronic mode to those Members whose e-mail addresses are registered with the Company/ Depositories. The Company has also sent a letter containing the web-link along with the path to access the Annual Report 2025-26 (including the Notice) to the Members whose email addresses are not registered with the Company/ RTA/ Depository Participant(s) pursuant to Regulation 36(1)(b) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (Listing Regulations). Members may note that the Notice of AGM and Annual Report 2025-26 is also available at the Company's website i.e., www.concordbiotech.com, website of Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and on the website of the Central Depository Services (India) Limited (agency providing remote e-voting facility and e-voting facility during the AGM) i.e., www.evotingindia.com. Members can attend and participate in the AGM through the VC / OAVM facility only. The instructions for joining the AGM are provided in the Notice of the AGM. Members attending the meeting through VC / OAVM shall be counted for the purpose of reckoning the quorum as per Section 103 of the Companies Act, 2013.

Notice is also hereby given that pursuant to Regulation 42 of Listing Regulations, the Company has fixed record date as Friday, July 24, 2026 for the purpose of identification of shareholders to whom dividend is to be paid and for the purpose of 41st AGM of the Company. Pursuant to the provisions of Section 108 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended and Regulation 44 of the Listing Regulations, members are provided with the facility to cast their vote electronically through remote e-voting as e-voting during the AGM services provided by the Central Depository Services (India) Limited on all resolutions as set forth in the 41st AGM Notice. The voting rights of the members shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as on Friday, July 24, 2026 ("cut-off date").

The remote e-voting period commences on Tuesday, July 28, 2026 (09:00 A.M. IST) and ends on Thursday, July 30, 2026 (05:00 P.M. IST). During this period, the Members may cast their vote electronically. The remote e-voting module shall be disabled by the Central Depository Services (India) Limited thereafter. Those Members, who shall be present in the AGM through VC/OAVM facility and had not cast their votes on the Resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.

The members who have cast their votes by remote e-voting prior to the AGM may also attend/participate in the AGM through VC/OAVM but shall not be entitled to cast their votes again.

Any person, who acquires shares of the Company and becomes a Member of the Company after the Notice has been sent electronically by the Company and holds shares as on the cut-off date, may obtain the log in ID and password by sending a request to helpdesk.helpdesk.evoting@cdsindia.com. However, if he/she is already registered with CDSL for remote e-voting, then he/she can use his/her existing User ID and password for casting the votes.

The manner of remote e-voting and voting at the AGM by members holding shares in dematerialized mode, physical mode and process to register e-mail addresses for members who have not registered their email addresses is provided in the Notice of the 41st AGM.


In case Member(s) have not registered their e-mail addresses with the Company/ Depository, please follow the below instructions to register e-mail address for obtaining Annual Report and login details for e-voting - Members holding shares in Demat mode can get their E-mail ID registered by contacting their respective Depository Participant or by e-mail to complianceofficer@concordbiotech.com

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting system, you can write an email to helpdesk.evoting@cdsindia.com or contact at toll free no. 18002109911.

For **CONCORD BIOTECH LIMITED**
 Sd/- **Paritosh Trivedi**
 Company Secretary & Compliance Officer (ACS : 63623)
 Place : Ahmedabad
 Date : July 07, 2026

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES OR UNITS NOR IS IT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA, INITIAL PUBLIC OFFERING OF EQUITY SHARES OF CULT.FIT LIMITED (FORMERLY CULT.FIT PRIVATE LIMITED AND CUREFIT HEALTHCARE PRIVATE LIMITED) ON THE MAIN BOARD OF BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES" IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT



CULT.FIT LIMITED

(Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)

Our Company was originally incorporated as 'Cure Fit Healthcare Private Limited' as a private limited company under the Companies Act, 2013, at Bengaluru, Karnataka, pursuant to a certificate of incorporation dated May 24, 2016 issued by the Registrar of Companies, Central Registration Centre ("CRC"). Subsequently, the name of the Company changed to 'CureFit Healthcare Private Limited' pursuant to a Board resolution dated September 22, 2016 and special resolution passed by the Shareholders dated September 23, 2016 on account of re-branding 'CureFit' for branding and marketing purposes, and a fresh certificate of incorporation dated November 16, 2016 issued by the Registrar of Companies, Karnataka at Bangalore. Further, the name of the Company changed to 'Cult.Fit Private Limited' pursuant to a Board resolution dated March 3, 2026 and special resolution passed by the Shareholders dated March 13, 2026 on account of re-branding 'Cult.Fit' to reflect our Company's business identity and branding strategy, and a fresh certificate of incorporation dated April 29, 2026 issued by the Registrar of Companies, Central Processing Centre ("CPC"). Our Company was thereafter converted into a public limited company pursuant to a resolution passed by our Board on June 16, 2026 and resolution passed by our Shareholders on June 17, 2026 and the name of our Company changed to 'Cult.Fit Limited'. A fresh certificate of incorporation dated June 25, 2026 was issued by the CPC pursuant to conversion to a public limited company. For further details, including details in relation to the changes in the registered office of our Company, see "History and Certain Corporate Matters - Changes in our Registered Office" on page 295 of the draft red herring prospectus dated July 6, 2026 ("DRHP").

Corporate Identity Number: U74989TN2016PLC176669
 Registered Office: 3rd Floor, Plot No. 269, Sy. No. 439/1B, Rajiv Gandhi Road, Chennai, Sholinganallur, Saidapet, Kanchipuram - 600 119, Tamil Nadu, India
 Corporate Office: CureFit HQ, 17/17C - BDA, 18th Cross, Sector-3, HSR Layout, Bengaluru, - 560 102, Karnataka
 Tel: +91 9187219018; Website: www.cult.fit; Contact person: Siddharth Sharma, Company Secretary and Compliance Officer; E-mail: secretnal@cult.fit

OUR COMPANY IS A PROFESSIONALLY MANAGED COMPANY AND DOES NOT HAVE AN IDENTIFIABLE PROMOTER

INITIAL PUBLIC OFFERING OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF CULT.FIT LIMITED ("OUR COMPANY" OR "THE COMPANY") FOR CASH AT A PRICE OF ₹1 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹1 PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹1 MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹9,500.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 178,609,200 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS CONSISTING OF UP TO 24,664,113 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY MACRITCHIE INVESTMENTS PTE. LTD., UP TO 19,537,242 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY FITNESS FIRST LUXEMBOURG S.C.A., UP TO 17,038,233 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY IIG VENTURES INDIA FUND III LLC, UP TO 15,862,353 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY TATA DIGITAL PRIVATE LIMITED, UP TO 11,056,131 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY CHIRATAE TRUST REPRESENTED BY ITS TRUSTEE VISTRAL ITC (INDIA) LIMITED AND ACTING THROUGH ITS INVESTMENT MANAGER, NAIGAMA INVESTMENT MANAGER LLP, UP TO 9,915,315 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY SCHROEDERS CAPITAL PRIVATE EQUITY ASIA MAURITIUS IV LIMITED, UP TO 7,912,322 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY TWENTY NINE CAPITAL PARTNERS LIMITED PARTNERSHIP (ACTING AT ALL TIMES THROUGH ITS GENERAL PARTNER, TWENTY NINE CAPITAL PARTNERS (GENERAL PARTNER) LIMITED), UP TO 6,532,434 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY ACCEL INDIA V (MAURITIUS) LIMITED, UP TO 6,165,096 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY ACCEL INDIA IV (MAURITIUS) LIMITED, UP TO 5,222,078 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY EPIQ CAPITAL B. L.P., UP TO 4,130,615 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY KALAARI CAPITAL PARTNERS III, L.L.C., UP TO 3,278,461 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY KALAARI CAPITAL PARTNERS OPPORTUNITY FUND, L.L.C., UP TO 2,316,969 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY VALECHA INVESTMENTS PRIVATE LIMITED, UP TO 1,160,568 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY SATYADHARMA INVESTMENTS AND TRADING COMPANY PRIVATE LIMITED, UP TO 1,024,116 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY CASTLE INVESTMENT AND INDUSTRIES PRIVATE LIMITED, UP TO 941,731 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY ANANTH SANKARANARAYANAN FAMILY TRUST, UP TO 816,051 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY SUN N SAND HOTELS PRIVATE LIMITED, UP TO 729,958 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY VENKTESH INVESTMENT AND TRADING COMPANY PRIVATE LIMITED, UP TO 686,412 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY ENDIYA SEED CO-CREATION FUND (A SCHEME OF ENDIYA TRUST, ACTING THROUGH ITS TRUSTEE, ENDIYA TRUSTEE PRIVATE LIMITED), UP TO 641,784 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY EXTREME BRANDS LLP, UP TO 486,609 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY ONYX SHAREHOLDERS LLC, UP TO 363,065 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY DOLI TRADING AND INVESTMENTS PRIVATE LIMITED (THE "INVESTOR SELLING SHAREHOLDERS"), UP TO 16,021,780 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY MUKESH BANSAI, UP TO 16,212,631 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY BRUNO EDUARD RASCHLE, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY JAMES SHA, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY ASAF AVIDAN ANTONIR, UP TO 907,287 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY KARAN HARESH MOTWANI, UP TO 907,284 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY NEHA KARAN MOTWANI, UP TO 633,813 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY HRITHIK RAKESH ROSHAN, UP TO 610,000 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY GUL RAMCHAND ADVANI, UP TO 467,335 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY VILAS S DHAR, UP TO 211,245 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY MUKUL DEORAS, UP TO 138,016 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY VIJAY KUMAR TAPARIA, UP TO 49,849 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY SHRADDHA SHETH, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹1 MILLION BY NIKHIL KAKKAR (THE "INDIVIDUAL SELLING SHAREHOLDERS") COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS", AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE", AND TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A PRE-IPO PLACEMENT OF SPECIFIED SECURITIES AGGREGATING UP TO ₹1,900.00 MILLION, AS MAY BE PERMITTED UNDER THE APPLICABLE LAW, AT ITS DISCRETION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER, OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND THE PROSPECTUS AND DETAILS OF THE PRE-IPO PLACEMENT, IF ANY, SHALL BE REPORTED TO THE STOCK EXCHANGES WITHIN 24 HOURS OF SUCH TRANSACTIONS, IN ACCORDANCE WITH REGULATION 54 OF THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company in consultation with the BRLMs and each of the Selling Shareholders, may for reasons to be recorded in writing, extend the Bid Offer Period for a minimum of one Working Day, subject to the Bid Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and intimation to Self-Certified Syndicate Banks ("SCSBs"), the Designated Intermediaries (as defined hereinafter) and the Sponsor Banks, (as defined hereinafter) as applicable.

This is an Offer in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. This Offer is being made through the Book Building Process in compliance with Regulation 6(2) of the SEBI ICDR Regulations wherein in terms of Regulation 32(2) of the SEBI ICDR Regulations not less than 75% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") and such portion of the "QIB Portion" provided that our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"). 40% of the Anchor Investor Portion shall be reserved as follows: (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds and Life Insurance Companies and Pension Funds at or above the price at which Equity Shares will be allocated to Anchor Investors ("Anchor Investor Allocation Price") in accordance with the SEBI ICDR Regulations and any under-subscription of 6.67% of the Anchor Investor Portion reserved for Life Insurance Companies and Pension Funds, such under-subscription portion may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be allotted to QIBs, then the entire Bid Amount (as defined hereinafter) will be refunded forthwith. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Offer shall be available for allocation to NBIs of which (a) one third portion shall be reserved for Bidders with application size of more than ₹20 million and up to ₹1.00 million; and (b) two-thirds of the portion shall be reserved for Bidders with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to Bidders in other sub-category of the NBIs in accordance with SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, not more than 10% of the Offer shall be available for allocation to Retail Individual Bidders ("RIB") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts (including UPI ID (defined hereinafter) in case of UPI Bidders (defined hereinafter) using the UPI Mechanism (defined hereinafter)), in which case the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable to participate in the Offer. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" on page 536 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP, on July 7, 2026 with the Stock Exchanges and Securities and Exchange Board of India ("SEBI"). Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of publication of this public announcement by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE at www.bseindia.com and NSE at www.nseindia.com, on the website of the Company at www.cult.fit, and on the websites of the Book Running Lead Managers ("BRLMs"), i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jeffries.com, www.mfi.com and www.morganstanley.com, respectively. Our Company invites the public to give their comments on the DRHP filed with SEBI and the Stock Exchanges, with respect to disclosures made in the DRHP. The public is requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Offer on or before 5:00 p.m. on the 21st day from the date of publication of this public announcement in accordance with Regulation 26(2) of the SEBI ICDR Regulations.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" beginning on page 21 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when issued through the RHP, are proposed to be listed on the Stock Exchanges.

For details of the share capital and capital structure and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, please see the section titled "Capital Structure" on page 104 of the DRHP. The liability of the members of our Company is limited by their shares. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on page 298 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER	
Axis Capital Limited 1 st Floor, Axis House P.B. Marg Worli Mumbai - 400 025 Maharashtra, India Tel: +91 22 4325 2183 E-mail: cultfit ipo@axiscap.in Website: www.axiscapital.co.in Investor Grievance ID: complaints@axiscap.in Contact Person: Pavan Naik SEBI Registration Number: INM000012029	Goldman Sachs (India) Securities Private Limited 10 th Floor Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai - 400 025 Maharashtra, India Tel: +91 22 6616 9000 E-mail: gs-cultfit@gs.com Website: www.goldmansachs.com Investor Grievance ID: india-client-support@gs.com Contact Person: Achint Parmarandaria/Harsh Parekh SEBI Registration Number: INM000011054	Jefferies India Private Limited Level 16, Express Towers, Nariman Point, Mumbai - 400 021, Maharashtra, India Tel: +91 22 4356 6000 E-mail: Cultfit.IPO@jefferies.com Website: www.jeffries.com Investor Grievance ID: jipl.grievance@jefferies.com Contact Person: Nidhi Rana, Vriti Menghrajani SEBI Registration Number: INM000011443	JM Financial Limited 7 th Floor, Energy, Appasaheb Marathe Marg, Prabhadevi Mumbai - 400 025 Maharashtra, India Tel: +91 22 6630 3030 E-mail: cultfit.ipo@jmf.com Website: www.jmf.com Investor grievance ID: grievance.ipo@jmf.com Contact Person: Prachee Dhuri, Vriti Menghrajani SEBI Registration No.: INM000010361	Morgan Stanley India Company Private Limited Altimus, Level 39 & 40, Pandurang Burchkar Marg, Worli, Mumbai - 400 018 Maharashtra, India Tel: +91 22 6118 1000 E-mail: cultfitipo@morganstanley.com Website: www.morganstanley.com Investor Grievance ID: investors_india@morganstanley.com Contact Person: Aditi Herga SEBI Registration No.: INM000011203	KFINTECH KFin Technologies Limited 301, The Centrum, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Kurla, Mumbai - 400 070, Maharashtra, India Tel: +91 40 6716 2222/180003094001 E-mail: cultfit.ipo@kfintech.com Website: www.kfintech.com Investor grievance e-mail: elnwardns@kfintech.com Contact Person: M. Murali Krishna SEBI Registration No.: INR000000221

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

Place: Chennai
 Date: July 7, 2026

CULT.FIT LIMITED (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited) is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on July 7, 2026. The DRHP is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.cult.fit; and on the websites of the BRLMs, i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jeffries.com, www.jmf.com and www.morganstanley.com, respectively. Any potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" on page 21 of the DRHP. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, when filed, for making any investment decision.

This announcement is not for publication or distribution to persons in the United States. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act ("Rule 144A")) and referred to in the Draft Red Herring Prospectus as "U.S. QIBs"; for the avoidance of doubt, the term U.S. QIBs does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the Draft Red Herring Prospectus as "QIBs" in one or more transactions exempt from the registration requirements of the U.S. Securities Act, and (ii) outside the United States in "offshore transactions", as defined in, and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.

For **CULT.FIT LIMITED**
 (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)
 On behalf of the Board of Directors
 Sd/-
Siddharth Sharma
 Company Secretary and Compliance Officer

Utkarsh Small Finance Bank
Aapki Ummeed Ka Khaata
 (A Scheduled Commercial Bank)

UTKARSH SMALL FINANCE BANK LIMITED
 CIN: L65992UP2016PLC082804

Registered Office: Utkarsh Tower, NH - 31 (Airport Road), Sehmalpur, Kazi Sarai, Harhua, Varanasi, Uttar Pradesh, PIN - 221105.
 Tel. No.: +91-542-660555 | Email: shareholders@utkarsh.bank.in
 Website: www.utkarsh.bank.in

NOTICE IS HEREBY GIVEN THAT THE TENTH (10th) ANNUAL GENERAL MEETING ("AGM") OF THE MEMBERS OF UTKARSH SMALL FINANCE BANK LIMITED ("USFB" OR "THE BANK") WILL BE HELD ON TUESDAY, AUGUST 04, 2026 AT 2.30 P.M., INDIAN STANDARD TIME ("IST") THROUGH VIDEO CONFERENCE ("VC") / OTHER AUDIO-VISUAL MEANS ("OAVM") TO TRANSACT THE BUSINESS AS SET OUT IN THE NOTICE OF THE AGM WHICH WILL BE CIRCULATED FOR CONVENING THE AGM.

- This is in compliance with the applicable provisions of the Companies Act, 2013 and the Rules made thereunder and Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") read with the Ministry of Corporate Affairs, Government of India ("MCA") Circular No. 03/2025 dated September 22, 2025 (in continuation with the Circulars issued earlier in this regard) ("MCA Circulars") and the SEBI vide various circulars issued in this regard ("SEBI Circulars") has permitted companies to hold AGM through VC or OAVM, without physical presence of the Members at a common venue.
 - The Notice of AGM and Annual Report of the Bank for the Financial Year 2025-26 will be sent electronically to those Members whose e-mail addresses are registered with the Bank/ Registrar and Transfer Agent ("RTA") i.e. KFin Technologies Limited ("KFIN") or with the Depository Participant ("DP"). The Bank shall send a physical copy of the Annual Report to those Members who request for the same at shareholders@utkarsh.bank.in mentioning their DP ID and Client ID.
 - All the shares of the Bank are Dematerialized form. Members holding shares in Dematerialized form and who have not registered/updated their e-mail addresses with the Depository Participants are requested to register/update their e-mail addresses and mobile numbers with their DP by following procedures prescribed by their DP.
 - The Bank has engaged the services of National Securities Depository Limited ("NSDL") for the purpose of providing e-voting facility to its Members to cast their votes on all resolutions set out in the Notice of 10th AGM. The details such as manner of (i) registering/updating email addresses, (ii) casting vote through remote e-voting/e-voting during the AGM and (iii) attending the AGM through VC/OAVM will be set out in the Notice of the AGM, which will be circulated through e-mail. The remote e-Voting facility would be available during the following period:
- | | |
|--------------------------|--|
| Commencement of e-Voting | Saturday, August 01, 2026 at 9:00 a.m. (IST) |
| End of e-Voting | Monday, August 03, 2026 at 5:00 p.m. (IST) |
- The Members are requested to carefully read all the Notes set out in the Notice of 10th AGM (being sent electronically) and particulars, instructions for joining AGM and manner of casting vote through remote e-voting or e-voting at the AGM.
 - The Notice of 10th AGM and the Annual Report for Financial Year 2025-26 will also be made available on the Bank's website www.utkarsh.bank.in and websites of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and also on the website of NSDL at www.evoting.nsdl.com
- For Utkarsh Small Finance Bank Limited
 Sd/-
Muthiah Ganapathy
 Company Secretary & Compliance Officer
- Date: July 08, 2026
 Place: Mumbai

CONCORD BIOTECH
Biotech for Mankind...

CONCORD BIOTECH LIMITED
 CIN : L24230GJ1984PLC007440

Regd. Off.: 1482-86, Trasad Road, Dholka, Ahmedabad - 382225, Gujarat, India
 Tel. No.: +91-79-68138725 | Email : compliance@concordbiotech.com
 Website : https://www.concordbiotech.com

NOTICE OF THE 41ST ANNUAL GENERAL MEETING, BOOK CLOSURE AND REMOTE E-VOTING INFORMATION

Notice is hereby given that the 41st Annual General Meeting ("AGM") of the Members of the Company will be held on **Friday, July 31, 2026 at 12:00 Noon** through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the business as set out in the Notice of AGM.

The Company has sent the Annual Report along with Notice convening 41st AGM on Tuesday, July 07, 2026, through electronic mode to all the Members whose e-mail IDs are registered with the Company's Registrar & Share Transfer Agent, M/s MUGF Intime India Private Limited / Depository Participant(s).

In accordance with the provisions of the Companies Act, 2013 ("the Act"), read with the Rules made thereunder and General Circular Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 5, 2020 and subsequent circulars issued in this regard, the latest being 03/2025 dated September 22, 2025, collectively referred to as "MCA Circulars", and other applicable circulars issued by the Securities and Exchange Board of India (SEBI) including Circular No. SEBI/HO/CFD/CFO-PoD-2/P/CIR/2024/133 dated October 3, 2024 ("SEBI Circulars"). AGM of the Company is being held through VC / OAVM.

In accordance with the aforesaid Circulars, Notice of AGM along with the Annual Report 2025-26 has been sent only by electronic mode to those Members whose e-mail addresses are registered with the Company/ Depositories. The Company has also sent a letter containing the web-link along with the path to access the Annual Report 2025-26 (including the Notice) to the Members whose email addresses are not registered with the Company/ RTA/ Depository Participant(s) pursuant to Regulation 36(1)(b) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (Listing Regulations). Members may note that the Notice of AGM and Annual Report 2025-26 is also available at the Company's website i.e. www.concordbiotech.com, website of Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and on the website of the Central Depository Services (India) Limited (agency providing remote e-voting facility and e-voting facility during the AGM) i.e. www.evotingindia.com. Members can attend and participate in the AGM through the VC / OAVM facility only. The instructions for joining the AGM are provided in the Notice of the AGM. Members attending the meeting through VC / OAVM shall be counted for the purpose of reckoning the quorum as per Section 103 of the Companies Act, 2013.

Notice is also hereby given that pursuant to Regulation 42 of Listing Regulations, the Company has fixed record date as Friday, July 24, 2026 for the purpose of identification of shareholders to whom dividend is to be paid and for the purpose of 41st AGM of the Company. Pursuant to the provisions of Section 108 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended and Regulation 44 of the Listing Regulations, members are provided with the facility to cast their vote electronically through remote e-voting as e-voting during the AGM services provided by the Central Depository Services (India) Limited on all resolutions as set forth in the 41st AGM Notice. The voting rights of the members shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as on Friday, July 24, 2026 ("cut-off date").

The remote e-voting period commences on Tuesday, July 28, 2026 (09:00 A.M. IST) and ends on Thursday, July 30, 2026 (05:00 P.M. IST). During this period, the Members may cast their vote electronically. The remote e-voting module shall be disabled by the Central Depository Services (India) Limited thereafter. Those Members, who shall be present in the AGM through VC/OAVM facility and had not cast their votes on the Resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.

The members who have cast their votes by remote e-voting prior to the AGM may also attend/participate in the AGM through VC/OAVM but shall not be entitled to cast their votes again.

Any person, who acquires shares of the Company and becomes a Member of the Company after the Notice has been sent electronically by the Company and holds shares as on the cut-off date, may obtain the log in ID and password by sending a request to helpdesk@concordbiotech.com. However, if he/she is already registered with CDSL for remote e-voting, then he/she can use his/her existing User ID and password for casting the votes.

The manner of remote e-voting and voting at the AGM by members holding shares in dematerialized mode, physical mode and process to register e-mail addresses for members who have not registered their email addresses is provided in the Notice of the 41st AGM.

In case Member(s) have not registered their e-mail addresses with the Company/ Depository, please follow the below instructions to register e-mail address for obtaining Annual Report and login details for e-voting -

Members holding shares in Demat mode can get their E-mail ID registered by contacting their respective Depository Participant or by e-mail to compliance@concordbiotech.com

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cbsindia.com or contact at toll free no. 18002109911.

For, **CONCORD BIOTECH LIMITED**
 Sd/- **Paritosh Trivedi**
 Company Secretary & Compliance Officer (ACS : 53623)

Place : Ahmedabad
 Date : July 07, 2026

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES OR UNITS NOR IS IT A PROSPECTUS. ANNOUNCEMENT, NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES OF CULT.FIT LIMITED (FORMERLY CULT.FIT PRIVATE LIMITED AND CUREFIT HEALTHCARE PRIVATE LIMITED) ON THE MAIN BOARD OF BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES" IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT



CULT.FIT LIMITED

(Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)

Our Company was originally incorporated as 'Cure Fit Healthcare Private Limited' as a private limited company under the Companies Act, 2013, at Bengaluru, Karnataka, pursuant to a certificate of incorporation dated May 24, 2016 issued by the Registrar of Companies, Central Registration Centre ("CRC"). Subsequently, the name of the Company changed to 'CureFit Healthcare Private Limited' pursuant to a Board resolution dated September 22, 2016 and special resolution passed by the Shareholders dated September 23, 2016 on account of re-branding 'CureFit' for branding and marketing purposes, and a fresh certificate of incorporation dated November 16, 2016 issued by the Registrar of Companies, Karnataka at Bengaluru. Further, the name of the Company changed to 'Cult.Fit Private Limited' pursuant to a Board resolution dated March 3, 2026 and special resolution passed by the Shareholders dated March 13, 2026 on account of re-branding 'Cult.Fit' to reflect our Company's business identity and branding strategy, and a fresh certificate of incorporation dated April 29, 2026 issued by the Registrar of Companies, Central Processing Centre ("CPC"). Our Company was thereafter converted into a public limited company pursuant to a resolution passed by our Board on June 16, 2026 and resolution passed by our Shareholders on June 17, 2026 and the name of our Company changed to 'Cult.Fit Limited'. A fresh certificate of incorporation dated June 25, 2026 was issued by the CPC pursuant to conversion to a public limited company. For further details, including details in relation to the changes in the registered office of our Company, see "History and Certain Corporate Matters - Changes in our Registered Office" on page 298 of the draft red herring prospectus dated July 6, 2026 ("DRHP").

Corporate Identity Number: U74999TN2016PLC176689
 Registered Office: 3rd Floor, Plot No. 269, Sy. No. 439/1B, Rajiv Gandhi Road, Chennai, Sholinganallur, Saidapet, Kanchipuram - 600 119, Tamil Nadu, India
 Corporate Office: Curefit HQ, 17/17C - BDA, 18th Cross, Sector-3, HSR Layout, Bengaluru, - 560 102, Karnataka
 Tel: +91 9187219018, Website: www.cult.fit, Contact person: Siddharth Sharma, Company Secretary and Compliance Officer; E-mail: secretarial@cult.fit

OUR COMPANY IS A PROFESSIONALLY MANAGED COMPANY AND DOES NOT HAVE AN IDENTIFIABLE PROMOTER

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF CULT.FIT LIMITED ("OUR COMPANY" OR "THE COMPANY") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹9,500.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 179,809,200 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS CONSISTING OF UP TO 24,684,113 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MACRITCHE INVESTMENTS PTE. LTD., UP TO 19,597,242 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY FITNESS FIRST LUXEMBOURG S.C.A., UP TO 17,038,233 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY IOG VENTURES INDIA FUND III LLC, UP TO 15,862,353 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY TATA DIGITAL PRIVATE LIMITED, UP TO 11,056,131 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY CHIRATAE TRUST REPRESENTED BY ITS TRUSTEE VISTRAL ITC (INDIA) LIMITED AND ACTING THROUGH ITS INVESTMENT MANAGER, NAIGAMA INVESTMENT MANAGER LLP, UP TO 9,915,315 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SCHROEDERS CAPITAL PRIVATE EQUITY ASIA MAURITIUS IV LIMITED, UP TO 7,912,322 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY TWENTY NINE CAPITAL PARTNERS LIMITED PARTNERSHIP (ACTING AT ALL TIMES THROUGH ITS GENERAL PARTNER, TWENTY NINE CAPITAL PARTNERS (GENERAL PARTNER) LIMITED), UP TO 6,532,434 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ACCEL INDIA V (MAURITIUS) LIMITED, UP TO 6,165,096 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ACCEL INDIA IV (MAURITIUS) LIMITED, UP TO 5,222,078 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY EPIO CAPITAL B, L.P., UP TO 4,130,615 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY KALAARI CAPITAL PARTNERS III, L.L.C., UP TO 3,278,461 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY KALAARI CAPITAL PARTNERS OPPORTUNITY FUND, L.L.C., UP TO 2,316,969 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VALECHA INVESTMENTS PRIVATE LIMITED, UP TO 1,160,568 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SATYADHARMA INVESTMENTS AND TRADING COMPANY PRIVATE LIMITED, UP TO 1,024,116 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY CASTLE INVESTMENT AND INDUSTRIES PRIVATE LIMITED, UP TO 941,731 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ANANTH SANKARANARAYANAN FAMILY TRUST, UP TO 816,081 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SUN N SANDS HOTEL PRIVATE LIMITED, UP TO 729,958 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VENKTESH INVESTMENT AND TRADING COMPANY PRIVATE LIMITED, UP TO 686,412 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ENDIYA SEED CO-CREATION FUND (A SCHEME OF ENDIYA TRUST, ACTING THROUGH ITS TRUSTEE, ENDIYA TRUSTEE PRIVATE LIMITED), UP TO 641,784 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY EXTREME BRANDS LLP, UP TO 486,609 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ONYX SHAREHOLDERS L.L.C., UP TO 363,065 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY DOLI TRADING AND INVESTMENTS PRIVATE LIMITED (THE "INVESTOR SELLING SHAREHOLDERS"), UP TO 16,021,780 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MUKESH BANSAI, UP TO 16,212,631 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY BRUNO EDUARD RASCHLE, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY JAMES SHA, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ASAF AVIDAN ANTONIR, UP TO 907,287 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY KARAN HARESH MOTWANI, UP TO 907,284 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY NEHA KARAN MOTWANI, UP TO 633,813 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY HRITHIK RAKESH ROSHAN, UP TO 610,000 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY GUL RAMCHAND ADVANI, UP TO 467,333 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VILAS S DHAR, UP TO 211,245 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MUKUL DEORAS, UP TO 138,016 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VIJAY KUMAR TAPARIA, UP TO 49,849 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SHRADHA SHETH, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY PRASHANT SUDHAKAR MACHWE, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY NIKHIL KAKKAR (THE "INDIVIDUAL SELLING SHAREHOLDERS") (COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS", AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE", AND TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A PRE-IPO PLACEMENT OF SPECIFIED SECURITIES AGGREGATING UP TO ₹1,000.00 MILLION, AS MAY BE PERMITTED UNDER THE APPLICABLE LAW, AT ITS DISCRETION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER, OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND THE PROSPECTUS AND DETAILS OF THE PRE-IPO PLACEMENT, IF ANY, SHALL BE REPORTED TO THE STOCK EXCHANGES WITHIN 24 HOURS OF SUCH TRANSACTIONS, IN ACCORDANCE WITH REGULATION 54 OF THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company in consultation with the BRLMs and each of the Selling Shareholders, may for reasons to be recorded in writing, extend the Bid Offer Period for a minimum of one Working Day, subject to the Bid Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and intimation to Self-Certified Syndicate Banks ("SCSBs"), the Designated Intermediaries (as defined hereinafter) and the Sponsor Banks, (as defined hereinafter) as applicable.

This is an Offer in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. This Offer is being made through the Book Building Process in compliance with Regulation 6(2) of the SEBI ICDR Regulations wherein in terms of Regulation 32(2) of the SEBI ICDR Regulations not less than 75% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") and such portion of the "QIB Portion" provided that our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"). 40% of the Anchor Investor Portion shall be reserved as follows: (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds and Life Insurance Companies and Pension Funds at or above the price at which Equity Shares will be allocated to Anchor Investors ("Anchor Investor Allocation Price") in accordance with the SEBI ICDR Regulations and any under-subscription of 6.67% of the Anchor Investor Portion reserved for Life Insurance Companies and Pension Funds, such under-subscription portion may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be allotted to QIBs, then the entire Bid Amount (as defined hereinafter) will be refunded forthwith. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Offer shall be available for allocation to NBIs of which (a) one third portion shall be reserved for Bidders with application size of more than ₹20 million and up to ₹1.00 million; and (b) two-thirds of the portion shall be reserved for Bidders with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to Bidders in other sub-category of the NBIs in accordance with SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, not more than 10% of the Offer shall be available for allocation to Retail Individual Bidders ("RIB") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts (including UPI ID (defined hereinafter) in case of UPI Bidders (defined hereinafter) using the UPI Mechanism (defined hereinafter)), in which case the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable to participate in the Offer. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" on page 536 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP, on July 7, 2026 with the Stock Exchanges and Securities and Exchange Board of India ("SEBI"). Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of publication of this public announcement by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE at www.bseindia.com and NSE at www.nseindia.com, on the website of the Company at www.cult.fit; and on the websites of the Book Running Lead Managers ("BRLMs"), i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jefferies.com, www.jmfi.com and www.morganstanley.com, respectively. Our Company invites the public to give their comments on the DRHP filed with SEBI and the Stock Exchanges, with respect to disclosures made in the DRHP. The public is requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Offer on or before 5:00 p.m. on the 21st day from the date of publication of this public announcement in accordance with Regulation 26(2) of the SEBI ICDR Regulations.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" beginning on page 21 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when issued through the RHP, are proposed to be listed on the Stock Exchanges.

For details of the share capital and capital structure and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, please see the section titled "Capital Structure" on page 104 of the DRHP. The liability of the members of our Company is limited by their shares. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on page 298 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER	
Axis Capital Limited 1 st Floor, Axis House P.B. Marg Worli Mumbai - 400 025 Maharashtra, India Tel: +91 22 4325 2183 E-mail: cultfit ipo@axiscap.in Website: www.axiscapital.co.in Investor Grievance ID: complaints@axiscap.in Contact Person: Pavan Naik SEBI Registration Number: INM000012029	Goldman Sachs (India) Securities Private Limited 10 th Floor Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai - 400 025 Maharashtra, India Tel: +91 22 6616 9000 E-mail: gs-cultfit@gs.com Website: www.goldmansachs.com Investor Grievance ID: india-client-support@gs.com Contact Person: Achint Parmar/Anandkhar Harsh Parekh SEBI Registration Number: INM000011054	Jefferies India Private Limited Level 16, Express Towers, Nariman Point, Mumbai - 400 021, Maharashtra, India Tel: +91 22 4356 6000 E-mail: Cultfit.IPO@jefferies.com Website: www.jefferies.com Investor Grievance ID: jpl.grievance@jefferies.com Contact Person: Nidhi Rana, Vrili Mengrajani SEBI Registration Number: INM000011443	JM Financial Limited 7 th Floor, Energy, Appasaheb Marathe Marg, Prabhadevi Mumbai - 400 025 Maharashtra, India Tel: +91 22 6630 3030 E-mail: cultfit.ipo@jmfi.com Website: www.jmfi.com Investor grievance ID: grievance.lbd@jmfi.com Contact Person: Prachee Dhuri SEBI Registration No: INM000010361	Morgan Stanley India Company Private Limited Altimus, Level 39 & 40, Pandurang Bhukar Marg, Worli, Mumbai - 400 018 Maharashtra, India Tel: + 91 22 6118 1000 E-mail: cultfitipo@morganstanley.com Website: www.morganstanley.com Investor Grievance ID: investors_india@morganstanley.com Contact Person: Adith Herga SEBI Registration No.: INM000011203	KFIN Technologies Limited 301, The Centrum, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Kurla, Mumbai - 400 070, Maharashtra, India Tel: +91 40 6716 2222/18003094001 E-mail: cultfit.ipo@kfintech.com Website: www.kfintech.com Investor grievance e-mail: inward@kfintech.com Contact Person: M. Murali Krishna SEBI Registration No.: INR000000221

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For **CULT.FIT LIMITED**
 (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)
 On behalf of the Board of Directors
 Sd/-
Siddharth Sharma
 Company Secretary and Compliance Officer

Place: Chennai
 Date: July 7, 2026

CULT.FIT LIMITED (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited) is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on July 7, 2026. The DRHP is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.cult.fit; and on the websites of the BRLMs, i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jefferies.com, www.jmfi.com and www.morganstanley.com, respectively. Any potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" on page 21 of the DRHP. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, when filed, for making any investment decision.

This announcement is not for publication or distribution to persons in the United States. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act ("Rule 144A")) and referred to in the Draft Red Herring Prospectus as "QIBs", for the avoidance of doubt, the term U.S. QIBs does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the Draft Red Herring Prospectus as "QIBs" in one or more transactions exempt from the registration requirements of the U.S. Securities Act; and (ii) outside the United States in "offshore transactions", as defined in, and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.

For, **CONCORD BIOTECH LIMITED**
 Sd/- **Paritosh Trivedi**
 Company Secretary & Compliance Officer (ACS : 53623)

Place : Ahmedabad
 Date : July 07, 2026



Utkarsh Small Finance Bank
Aapki Ummeed Ka Khaata
 (A Scheduled Commercial Bank)
UTKARSH SMALL FINANCE BANK LIMITED
 CIN: L65992UP2016PLC082804
 Registered Office: Utkarsh Tower, NH - 31 (Airport Road), Sehmalpur, Kazi Sarai, Harhua, Varanasi, Uttar Pradesh, PIN - 221105.
 Tel. No.: +91-542-6605555 | Email: shareholders@utkarsh.bank.in
 Website: www.utkarsh.bank.in

NOTICE IS HEREBY GIVEN THAT THE TENTH (10th) ANNUAL GENERAL MEETING ("AGM") OF THE MEMBERS OF UTKARSH SMALL FINANCE BANK LIMITED ("USFBL" OR "THE BANK") WILL BE HELD ON TUESDAY, AUGUST 04, 2026 AT 2.30 P.M., INDIAN STANDARD TIME ("IST") THROUGH VIDEO CONFERENCE ("VC") / OTHER AUDIO-VISUAL MEANS ("OAVM") TO TRANSACT THE BUSINESS AS SET OUT IN THE NOTICE OF THE AGM WHICH WILL BE CIRCULATED FOR CONVENING THE AGM.

- This is in compliance with the applicable provisions of the Companies Act, 2013 and the Rules made thereunder and Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") read with the Ministry of Corporate Affairs, Government of India ("MCA") Circular No. 03/2025 dated September 22, 2025 (in continuation with the Circulars issued earlier in this regard) ("MCA Circulars") and the SEBI vide various circulars issued in this regard ("SEBI Circulars") has permitted companies to hold AGM through VC or OAVM, without physical presence of the Members at a common venue.
- The Notice of AGM and Annual Report of the Bank for the Financial Year 2025-26 will be sent electronically to those Members whose e-mail addresses are registered with the Bank/ Registrar and Transfer Agent ("RTA") i.e. KFin Technologies Limited ("KFIN") or with the Depository Participant ("DP"). The Bank shall send a physical copy of the Annual Report to those Members who request for the same at shareholders@utkarsh.bank.in mentioning their DP ID and Client ID.
- All the shares of the Bank are Dematerialized form. Members holding shares in Dematerialized form and who have not registered/updated their e-mail addresses with the Depository Participants are requested to register/update their e-mail addresses and mobile numbers with their DP by following procedures prescribed by their DP.
- The Bank has engaged the services of National Securities Depository Limited ("NSDL") for the purpose of providing e-voting facility to its Members to cast their votes on all resolutions set out in the Notice of 10th AGM. The details such as manner of (i) registering/updating email addresses, (ii) casting vote through remote e-voting/e-voting during the AGM and (iii) attending the AGM through VC/OAVM will be set out in the Notice of the AGM, which will be circulated through e-mail. The remote e-Voting facility would be available during the following period:

Commencement of e-Voting	Saturday, August 01, 2026 at 9:00 a.m. (IST)
End of e-Voting	Monday, August 03, 2026 at 5:00 p.m. (IST)

For Utkarsh Small Finance Bank Limited
 Sd/-
Muthiah Ganapathy
 Company Secretary & Compliance Officer
 Date: July 08, 2026
 Place: Mumbai

CONCORD BIOTECH
Biotech for Mankind...
CONCORD BIOTECH LIMITED
 CIN : L24230GJ1984PLC007440
 Regd. Off.: 1482-86, Trasad Road, Dholka, Ahmedabad - 382225, Gujarat, India
 Tel. No.: +91-79-68138725 | Email: compliance@concordbiotech.com
 Website: https://www.concordbiotech.com

NOTICE OF THE 41ST ANNUAL GENERAL MEETING, BOOK CLOSURE AND REMOTE E-VOTING INFORMATION

Notice is hereby given that the 41st Annual General Meeting ("AGM") of the Members of the Company will be held on **Friday, July 31, 2026 at 12:00 Noon** through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the business as set out in the Notice of AGM. The Company has sent the Annual Report along with Notice convening 41st AGM on Tuesday, July 07, 2026, through electronic mode to all the Members whose e-mail IDs are registered with the Company's Registrar & Share Transfer Agent, M/s MUFG Intime India Private Limited / Depository Participant(s). In accordance with the provisions of the Companies Act, 2013 ("the Act"), read with the Rules made thereunder and General Circular Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 5, 2020 and subsequent circulars issued in this regard, the latest being 03/2025 dated September 22, 2025, collectively referred to as "MCA Circulars", and other applicable circulars issued by the Securities and Exchange Board of India (SEBI) including Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024 ("SEBI Circulars"). AGM of the Company is being held through VC / OAVM.

In accordance with the aforesaid Circulars, Notice of AGM along with the Annual Report 2025-26 has been sent only by electronic mode to those Members whose e-mail addresses are registered with the Company/ Depositories. The Company has also sent a letter containing the web-link along with the path to access the Annual Report 2025-26 (including the Notice) to the Members whose email addresses are not registered with the Company/ RTA/ Depository Participant(s) pursuant to Regulation 36(1)(b) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (Listing Regulations). Members may note that the Notice of AGM and Annual Report 2025-26 is also available at the Company's website i.e., www.concordbiotech.com, website of Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and on the website of the Central Depository Services (India) Limited (agency providing remote e-voting facility and e-voting facility during the AGM) i.e., www.evotingindia.com. Members can attend and participate in the AGM through the VC / OAVM facility only. The instructions for joining the AGM are provided in the Notice of the AGM. Members attending the meeting through VC / OAVM shall be counted for the purpose of reckoning the quorum as per Section 103 of the Companies Act, 2013.

Notice is also hereby given that pursuant to Regulation 42 of Listing Regulations, the Company has fixed record date as Friday, July 24, 2026 for the purpose of identification of shareholders to whom dividend is to be paid and for the purpose of 41st AGM of the Company. Pursuant to the provisions of Section 108 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended and Regulation 44 of the Listing Regulations, members are provided with the facility to cast their vote electronically through remote e-voting as e-voting during the AGM services provided by the Central Depository Services (India) Limited on all resolutions as set forth in the 41st AGM Notice. The voting rights of the members shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as on Friday, July 24, 2026 ("cut-off date").

The remote e-voting period commences on Tuesday, July 28, 2026 (09:00 A.M. IST) and ends on Thursday, July 30, 2026 (05:00 P.M. IST). During this period, the Members may cast their votes electronically. The remote e-voting module shall be disabled by the Central Depository Services (India) Limited thereafter. Those Members, who shall be present in the AGM through VC/OAVM facility and had not cast their votes on the Resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.

The members who have cast their votes by remote e-voting prior to the AGM may also attend/participate in the AGM through VC/OAVM but shall not be entitled to cast their votes again.


Any person, who acquires shares of the Company and becomes a Member of the Company after the Notice has been sent electronically by the Company and holds shares as on the cut-off date, may obtain the log in ID and password by sending a request to helpdesk.helpdesk.evoting@cdsindia.com. However, if he/she is already registered with CDSL for remote e-voting, then he/she can use his/her existing User ID and password for casting the votes. The manner of remote e-voting and voting at the AGM by members holding shares in dematerialized mode, physical mode and process to register e-mail addresses for members who have not registered their email addresses is provided in the Notice of the 41st AGM.

In case Member(s) have not registered their e-mail addresses with the Company/ Depository, please follow the below instructions to register e-mail address for obtaining Annual Report and login details for e-voting - Members holding shares in Demat mode can get their E-mail ID registered by contacting their respective Depository Participant or by e-mail to complianceofficer@concordbiotech.com
 If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting system, you can write an email to helpdesk.evoting@cdsindia.com or contact at toll free no. 18002109911.

For **CONCORD BIOTECH LIMITED**
 Sd/- **Paritosh Trivedi**
 Company Secretary & Compliance Officer (ACS : 63623)
 Place : Ahmedabad
 Date : July 07, 2026

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES OR UNITS NOR IS IT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES OF CULT.FIT LIMITED (FORMERLY CULT.FIT PRIVATE LIMITED AND CUREFIT HEALTHCARE PRIVATE LIMITED) ON THE MAIN BOARD OF BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES" IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT



CULT.FIT LIMITED

(Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)

Our Company was originally incorporated as 'Cure Fit Healthcare Private Limited' as a private limited company under the Companies Act, 2013, at Bengaluru, Karnataka, pursuant to a certificate of incorporation dated May 24, 2016 issued by the Registrar of Companies, Central Registration Centre ("CRC"). Subsequently, the name of the Company changed to 'CureFit Healthcare Private Limited' pursuant to a Board resolution dated September 22, 2016 and special resolution passed by the Shareholders dated September 23, 2016 on account of re-branding 'CureFit' for branding and marketing purposes, and a fresh certificate of incorporation dated November 16, 2016 issued by the Registrar of Companies, Karnataka at Bangalore. Further, the name of the Company changed to 'Cult.Fit Private Limited' pursuant to a Board resolution dated March 3, 2026 and special resolution passed by the Shareholders dated March 13, 2026 on account of re-branding 'Cult.Fit' to reflect our Company's business identity and branding strategy, and a fresh certificate of incorporation dated April 29, 2026 issued by the Registrar of Companies, Central Processing Centre ("CPC"). Our Company was thereafter converted into a public limited company pursuant to a resolution passed by our Board on June 16, 2026 and resolution passed by our Shareholders on June 17, 2026 and the name of our Company changed to 'Cult.Fit Limited'. A fresh certificate of incorporation dated June 25, 2026 was issued by the CPC pursuant to conversion to a public limited company. For further details, including details in relation to the changes in the registered office of our Company, see "History and Certain Corporate Matters - Changes in our Registered Office" on page 295 of the draft red herring prospectus dated July 6, 2026 ("DRHP").

Corporate Identity Number: U74989TN2016PLC176669
 Registered Office: 3rd Floor, Plot No. 269, Sy. No. 439/1B, Rajiv Gandhi Road, Chennai, Sholinganallur, Saidapet, Kanchipuram - 600 119, Tamil Nadu, India
 Corporate Office: CureFit HQ, 17/17C - BDA, 18th Cross, Sector-3, HSR Layout, Bengaluru, - 560 102, Karnataka
 Tel: +91 9187219018; Website: www.cult.fit; Contact person: Siddharth Sharma, Company Secretary and Compliance Officer; E-mail: secretnal@cult.fit

OUR COMPANY IS A PROFESSIONALLY MANAGED COMPANY AND DOES NOT HAVE AN IDENTIFIABLE PROMOTER

INITIAL PUBLIC OFFERING OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF CULT.FIT LIMITED ("OUR COMPANY" OR "THE COMPANY") FOR CASH AT A PRICE OF ₹[•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[•] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[•] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹9,500.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 178,609,200 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS CONSISTING OF UP TO 24,664,113 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY MACRITCHE INVESTMENTS PTE. LTD., UP TO 19,537,242 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY FITNESS FIRST LUXEMBOURG S.C.A., UP TO 17,038,233 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY IIG VENTURES INDIA FUND III LLC, UP TO 15,862,353 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY TATA DIGITAL PRIVATE LIMITED, UP TO 11,056,131 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY CHIRATAE TRUST REPRESENTED BY ITS TRUSTEE VISTRAL ITC (INDIA) LIMITED AND ACTING THROUGH ITS INVESTMENT MANAGER, NAIGAMA INVESTMENT MANAGER LLP, UP TO 9,915,315 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY SCHROEDERS CAPITAL PRIVATE EQUITY ASIA MAURITIUS IV LIMITED, UP TO 7,912,322 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY TWENTY NINE CAPITAL PARTNERS LIMITED PARTNERSHIP (ACTING AT ALL TIMES THROUGH ITS GENERAL PARTNER, TWENTY NINE CAPITAL PARTNERS (GENERAL PARTNER) LIMITED), UP TO 6,532,434 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY ACCEL INDIA V (MAURITIUS) LIMITED, UP TO 6,165,096 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY ACCEL INDIA IV (MAURITIUS) LIMITED, UP TO 16,021,780 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY MUKESH BANSAI, UP TO 16,212,631 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY BRUNO EDUARD RASCHLE, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY JAMES SHA, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY ASAF AVIDAN ANTONIR, UP TO 907,287 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY KARAN HARESH MOTWANI, UP TO 907,284 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY NEHA KARAN MOTWANI, UP TO 633,813 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY HRITHIK RAKESH ROSHAN, UP TO 610,000 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY GUL RAMCHAND ADVANI, UP TO 467,333 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY VILAS S DHAR, UP TO 211,245 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY MUKUL DEORAS, UP TO 138,016 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY VIJAY KUMAR TAPARIA, UP TO 49,849 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY SHRADDHA SHETH, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY NIKHIL KAKKAR (THE "INDIVIDUAL SELLING SHAREHOLDERS") COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS", AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE", AND TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A PRE-IPO PLACEMENT OF SPECIFIED SECURITIES AGGREGATING UP TO ₹1,900.00 MILLION, AS MAY BE PERMITTED UNDER THE APPLICABLE LAW, AT ITS DISCRETION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER, OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND THE PROSPECTUS AND DETAILS OF THE PRE-IPO PLACEMENT, IF ANY, SHALL BE REPORTED TO THE STOCK EXCHANGES WITHIN 24 HOURS OF SUCH TRANSACTIONS, IN ACCORDANCE WITH REGULATION 54 OF THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company in consultation with the BRLMs and each of the Selling Shareholders, may for reasons to be recorded in writing, extend the Bid Offer Period for a minimum of one Working Day, subject to the Bid Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and intimation to Self-Certified Syndicate Banks ("SCSBs"), the Designated Intermediaries (as defined hereinafter) and the Sponsor Banks, (as defined hereinafter) as applicable.

This is an Offer in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. This Offer is being made through the Book Building Process in compliance with Regulation 6(2) of the SEBI ICDR Regulations wherein in terms of Regulation 32(2) of the SEBI ICDR Regulations not less than 75% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") and such portion of the "QIB Portion" provided that our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"). 40% of the Anchor Investor Portion shall be reserved as follows: (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds and Life Insurance Companies and Pension Funds at or above the price at which Equity Shares will be allocated to Anchor Investors ("Anchor Investor Allocation Price") in accordance with the SEBI ICDR Regulations and any under-subscription of 6.67% of the Anchor Investor Portion reserved for Life Insurance Companies and Pension Funds, such under-subscription portion may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be allotted to QIBs, then the entire Bid Amount (as defined hereinafter) will be refunded forthwith. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Offer shall be available for allocation to NBIs of which (a) one third portion shall be reserved for Bidders with application size of more than ₹20 million and up to ₹1.00 million; and (b) two-thirds of the portion shall be reserved for Bidders with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to Bidders in other sub-category of the NBIs in accordance with SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, not more than 10% of the Offer shall be available for allocation to Retail Individual Bidders ("RIB") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts (including UPI ID (defined hereinafter) in case of UPI Bidders (defined hereinafter) using the UPI Mechanism (defined hereinafter)), in which case the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable to participate in the Offer. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" on page 536 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP, on July 7, 2026 with the Stock Exchanges and Securities and Exchange Board of India ("SEBI"). Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of publication of this public announcement by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE at www.bseindia.com and NSE at www.nseindia.com, on the website of the Company at www.cult.fit, and on the websites of the Book Running Lead Managers ("BRLMs"), i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jeffries.com, www.mfi.com and www.morganstanley.com, respectively. Our Company invites the public to give their comments on the DRHP filed with SEBI and the Stock Exchanges, with respect to disclosures made in the DRHP. The public is requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Offer on or before 5:00 p.m. on the 21st day from the date of publication of this public announcement in accordance with Regulation 26(2) of the SEBI ICDR Regulations.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" beginning on page 21 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when issued through the RHP, are proposed to be listed on the Stock Exchanges.

For details of the share capital and capital structure and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, please see the section titled "Capital Structure" on page 104 of the DRHP. The liability of the members of our Company is limited by their shares. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on page 298 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER	
					
Axis Capital Limited 1 st Floor, Axis House P.B. Marg Worli Mumbai - 400 025 Maharashtra, India Tel: +91 22 4325 2183 E-mail: cultfit ipo@axiscap.in Website: www.axiscapital.co.in Investor Grievance ID: complaints@axiscap.in Contact Person: Pavan Naik SEBI Registration Number: INM000012029	Goldman Sachs (India) Securities Private Limited 10 th Floor Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai - 400 025 Maharashtra, India Tel: +91 22 6616 9000 E-mail: gs-cultfit@gs.com Website: www.goldmansachs.com Investor Grievance ID: india-client-support@gs.com Contact Person: Achint Parmarandaria/Harsh Parekh SEBI Registration Number: INM000011054	Jefferies India Private Limited Level 16, Express Towers, Nariman Point, Mumbai - 400 021, Maharashtra, India Tel: +91 22 4356 6000 E-mail: Cultfit.IPO@jefferies.com Website: www.jeffries.com Investor Grievance ID: jipl.grievance@jefferies.com Contact Person: Nidhi Rana, Vriti Menghrajani SEBI Registration Number: INM000011443	JM Financial Limited 7 th Floor, Energy, Appasaheb Marathe Marg, Prabhadevi Mumbai - 400 025 Maharashtra, India Tel: +91 22 6630 3030 E-mail: cultfit.ipo@jmfi.com Website: www.jmfi.com Investor grievance ID: grievance.ipo@jmfi.com Contact Person: Prachee Dhuri SEBI Registration No: INM000010361	Morgan Stanley India Company Private Limited Altimus, Level 39 & 40, Pandurang Burchkar Marg, Worli, Mumbai - 400 018 Maharashtra, India Tel: +91 22 6118 1000 E-mail: cultfitipo@morganstanley.com Website: www.morganstanley.com Investor Grievance ID: investors_india@morganstanley.com Contact Person: Aditi Herga SEBI Registration No: INM000011203	KFINTECH KFin Technologies Limited 301, The Centrum, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Kurla, Mumbai - 400 070, Maharashtra, India Tel: +91 40 6716 2222/18003094001 E-mail: cultfit.ipo@kfintech.com Website: www.kfintech.com Investor grievance e-mail: elnw@kfin.com Contact Person: M. Murali Krishna SEBI Registration No.: INR000002021

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For **CULT.FIT LIMITED**
 (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)
 On behalf of the Board of Directors
 Sd/-
Siddharth Sharma
 Company Secretary and Compliance Officer
 Place: Chennai
 Date: July 7, 2026

CULT.FIT LIMITED (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited) is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on July 7, 2026. The DRHP is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.cult.fit; and on the websites of the BRLMs, i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jeffries.com, www.jmfi.com and www.morganstanley.com, respectively. Any potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" on page 21 of the DRHP. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, when filed, for making any investment decision.

This announcement is not for publication or distribution to persons in the United States. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act ("Rule 144A")) and referred to in the Draft Red Herring Prospectus as "U.S. QIBs"; for the avoidance of doubt, the term U.S. QIBs does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the Draft Red Herring Prospectus as "QIBs" in one or more transactions exempt from the registration requirements of the U.S. Securities Act, and (ii) outside the United States in "offshore transactions", as defined in, and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.

Utkarsh Small Finance Bank
Aapki Ummeed Ka Khaata
 (A Scheduled Commercial Bank)
UTKARSH SMALL FINANCE BANK LIMITED
 CIN: L65992UP2016PLC082804
 Registered Office: Utkarsh Tower, NH - 31 (Airport Road), Sehmalpur, Kazi Sarai, Harhua, Varanasi, Uttar Pradesh, PIN - 221105.
 Tel. No.: +91-542-6605555 | Email: shareholders@utkarsh.bank.in
 Website: www.utkarsh.bank.in

NOTICE IS HEREBY GIVEN THAT THE TENTH (10th) ANNUAL GENERAL MEETING ("AGM") OF THE MEMBERS OF UTKARSH SMALL FINANCE BANK LIMITED ("USFB" OR "THE BANK") WILL BE HELD ON TUESDAY, AUGUST 04, 2026 AT 2.30 P.M., INDIAN STANDARD TIME ("IST") THROUGH VIDEO CONFERENCE ("VC") / OTHER AUDIO-VISUAL MEANS ("OAVM") TO TRANSACT THE BUSINESS AS SET OUT IN THE NOTICE OF THE AGM WHICH WILL BE CIRCULATED FOR CONVENING THE AGM.

- This is in compliance with the applicable provisions of the Companies Act, 2013 and the Rules made thereunder and Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") read with the Ministry of Corporate Affairs, Government of India ("MCA") Circular No. 03/2025 dated September 22, 2025 (in continuation with the Circulars issued earlier in this regard) ("MCA Circulars") and the SEBI vide various circulars issued in this regard ("SEBI Circulars") has permitted companies to hold AGM through VC or OAVM, without physical presence of the Members at a common venue.
 - The Notice of AGM and Annual Report of the Bank for the Financial Year 2025-26 will be sent electronically to those Members whose e-mail addresses are registered with the Bank/ Registrar and Transfer Agent ("RTA") i.e. KFin Technologies Limited ("KFIN") or with the Depository Participant ("DP"). The Bank shall send a physical copy of the Annual Report to those Members who request for the same at shareholders@utkarsh.bank.in mentioning their DP ID and Client ID.
 - All the shares of the Bank are Dematerialized form. Members holding shares in Dematerialized form and who have not registered/updated their e-mail addresses with the Depository Participants are requested to register/update their e-mail addresses and mobile numbers with their DP by following procedures prescribed by their DP.
 - The Bank has engaged the services of National Securities Depository Limited ("NSDL") for the purpose of providing e-voting facility to its Members to cast their votes on all resolutions set out in the Notice of 10th AGM. The details such as manner of (i) registering/updating email addresses, (ii) casting vote through remote e-voting/e-voting during the AGM and (iii) attending the AGM through VC/OAVM will be set out in the Notice of the AGM, which will be circulated through e-mail. The remote e-Voting facility would be available during the following period:
- | | |
|--------------------------|--|
| Commencement of e-Voting | Saturday, August 01, 2026 at 9:00 a.m. (IST) |
| End of e-Voting | Monday, August 03, 2026 at 5:00 p.m. (IST) |
- The Members are requested to carefully read all the Notes set out in the Notice of 10th AGM (being sent electronically) and particulars, instructions for joining AGM and manner of casting vote through remote e-voting or e-voting at the AGM.
 - The Notice of 10th AGM and the Annual Report for Financial Year 2025-26 will also be made available on the Bank's website www.utkarsh.bank.in and websites of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and also on the website of NSDL at www.evoting.nsdl.com
- For Utkarsh Small Finance Bank Limited
 Sd/-
Muthiah Ganapathy
 Company Secretary & Compliance Officer
- Date: July 08, 2026
 Place: Mumbai

CONCORD BIOTECH
Biotech for Mankind...
CONCORD BIOTECH LIMITED
 CIN : L24230GJ1984PLC007440
 Regd. Off.: 1482-86, Trasad Road, Dholka, Ahmedabad - 382225, Gujarat, India
 Tel. No.: +91-79-68138725 | Email: compliance@concordbiotech.com
 Website: https://www.concordbiotech.com

NOTICE OF THE 41ST ANNUAL GENERAL MEETING, BOOK CLOSURE AND REMOTE E-VOTING INFORMATION

Notice is hereby given that the 41st Annual General Meeting ("AGM") of the Members of the Company will be held on **Friday, July 31, 2026 at 12:00 Noon** through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the business as set out in the Notice of AGM.

The Company has sent the Annual Report along with Notice convening 41st AGM on Tuesday, July 07, 2026, through electronic mode to all the Members whose e-mail IDs are registered with the Company's Registrar & Share Transfer Agent, M/s MUFG Intime India Private Limited / Depository Participant(s).

In accordance with the provisions of the Companies Act, 2013 ("the Act"), read with the Rules made thereunder and General Circular Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 5, 2020 and subsequent circulars issued in this regard, the latest being 03/2025 dated September 22, 2025, collectively referred to as "MCA Circulars", and other applicable circulars issued by the Securities and Exchange Board of India (SEBI) including Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024 ("SEBI Circulars"). AGM of the Company is being held through VC / OAVM.

In accordance with the aforesaid Circulars, Notice of AGM along with the Annual Report 2025-26 has been sent only by electronic mode to those Members whose e-mail addresses are registered with the Company/ Depositories. The Company has also sent a letter containing the web-link along with the path to access the Annual Report 2025-26 (including the Notice) to the Members whose email addresses are not registered with the Company/ RTA/ Depository Participant(s) pursuant to Regulation 36(1)(b) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (Listing Regulations). Members may note that the Notice of AGM and Annual Report 2025-26 is also available at the Company's website i.e. www.concordbiotech.com, website of Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and on the website of the Central Depository Services (India) Limited (agency providing remote e-voting facility and e-voting facility during the AGM) i.e. www.evotingindia.com. Members can attend and participate in the AGM through the VC / OAVM facility only. The instructions for joining the AGM are provided in the Notice of the AGM. Members attending the meeting through VC / OAVM shall be counted for the purpose of reckoning the quorum as per Section 103 of the Companies Act, 2013.

Notice is also hereby given that pursuant to Regulation 42 of Listing Regulations, the Company has fixed record date as Friday, July 24, 2026 for the purpose of identification of shareholders to whom dividend is to be paid and for the purpose of 41st AGM of the Company. Pursuant to the provisions of Section 108 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended and Regulation 44 of the Listing Regulations, members are provided with the facility to cast their vote electronically through remote e-voting or e-voting during the AGM services provided by the Central Depository Services (India) Limited on all resolutions as set forth in the 41st AGM Notice. The voting rights of the members shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as on Friday, July 24, 2026 ("cut-off date").

The remote e-voting period commences on Tuesday, July 28, 2026 (09:00 A.M. IST) and ends on Thursday, July 30, 2026 (05:00 P.M. IST). During this period, the Members may cast their votes electronically. The remote e-voting module shall be disabled by the Central Depository Services (India) Limited thereafter. Those Members, who shall be present in the AGM through VC/OAVM facility and had not cast their votes on the Resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.

The members who have cast their votes by remote e-voting prior to the AGM may also attend/participate in the AGM through VC/OAVM but shall not be entitled to cast their votes again.

Any person, who acquires shares of the Company and becomes a Member of the Company after the Notice has been sent electronically by the Company and holds shares as on the cut-off date, may obtain the log in ID and password by sending a request to helpdesk.helpdesk.evoting@cdslindia.com. However, if he/she is already registered with CDSL for remote e-voting, then he/she can use his/her existing User ID and password for casting the votes.

The manner of remote e-voting and voting at the AGM by members holding shares in dematerialized mode, physical mode and process to register e-mail addresses for members who have not registered their email addresses is provided in the Notice of the 41st AGM.

In case Member(s) have not registered their e-mail addresses with the Company/ Depository, please follow the below instructions to register e-mail address for obtaining Annual Report and login details for e-voting - Members holding shares in Demat mode can get their E-mail ID registered by contacting their respective Depository Participant or by e-mail to complianceofficer@concordbiotech.com


If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting system, you can write an email to helpdesk.evoting@cdslindia.com or contact at toll free no. 18002109911.

For **CONCORD BIOTECH LIMITED**
 Sd/- **Paritosh Trivedi**
 Company Secretary &
 Compliance Officer (ACS : 63623)

Place : Ahmedabad
 Date : July 07, 2026

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES OR UNITS NOR IS IT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES OF CULT.FIT LIMITED (FORMERLY CULT.FIT PRIVATE LIMITED AND CUREFIT HEALTHCARE PRIVATE LIMITED) ON THE MAIN BOARD OF BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES" IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT



CULT.FIT LIMITED

(Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)

Our Company was originally incorporated as 'Cure Fit Healthcare Private Limited' as a private limited company under the Companies Act, 2013, at Bengaluru, Karnataka, pursuant to a certificate of incorporation dated May 24, 2016 issued by the Registrar of Companies, Central Registration Centre ("CRC"). Subsequently, the name of the Company changed to 'CureFit Healthcare Private Limited' pursuant to a Board resolution dated September 22, 2016 and special resolution passed by the Shareholders dated September 23, 2016 on account of re-branding 'CureFit' for branding and marketing purposes, and a fresh certificate of incorporation dated November 16, 2016 issued by the Registrar of Companies, Karnataka at Bangalore. Further, the name of the Company changed to 'Cult.Fit Private Limited' pursuant to a Board resolution dated March 3, 2026 and special resolution passed by the Shareholders dated March 13, 2026 on account of re-branding 'Cult.Fit' to reflect our Company's business identity and branding strategy, and a fresh certificate of incorporation dated April 29, 2026 issued by the Registrar of Companies, Central Processing Centre ("CPC"). Our Company was thereafter converted into a public limited company pursuant to a resolution passed by our Board on June 16, 2026 and resolution passed by our Shareholders on June 17, 2026 and the name of our Company changed to 'Cult.Fit Limited'. A fresh certificate of incorporation dated June 25, 2026 was issued by the CPC pursuant to conversion to a public limited company. For further details, including details in relation to the changes in the registered office of our Company, see "History and Certain Corporate Matters - Changes in our Registered Office" on page 295 of the draft red herring prospectus dated July 6, 2026 ("DRHP").

Corporate Identity Number: U74989TN2016PLC176669
 Registered Office: 3rd Floor, Plot No. 269, Sy. No. 439/1B, Rajiv Gandhi Road, Chennai, Sholinganallur, Saidapet, Kanchipuram - 600 119, Tamil Nadu, India
 Corporate Office: CureFit HQ, 17/17C - BDA, 18th Cross, Sector-3, HSR Layout, Bengaluru, - 560 102, Karnataka
 Tel: +91 9187219018; Website: www.cult.fit; Contact person: Siddharth Sharma, Company Secretary and Compliance Officer; E-mail: secretnal@cult.fit

OUR COMPANY IS A PROFESSIONALLY MANAGED COMPANY AND DOES NOT HAVE AN IDENTIFIABLE PROMOTER

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF CULT.FIT LIMITED ("OUR COMPANY" OR "THE COMPANY") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹9,500.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 178,609,200 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS CONSISTING OF UP TO 24,664,113 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MACRITCHIE INVESTMENTS PTE. LTD., UP TO 19,537,242 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY FITNESS FIRST LUXEMBOURG S.C.A., UP TO 17,038,233 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY IIG VENTURES INDIA FUND III LLC, UP TO 15,862,353 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY TATA DIGITAL PRIVATE LIMITED, UP TO 11,056,131 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY CHIRATAE TRUST REPRESENTED BY ITS TRUSTEE VISTRAL ITC (INDIA) LIMITED AND ACTING THROUGH ITS INVESTMENT MANAGER, NAIGAMA INVESTMENT MANAGER LLP, UP TO 9,915,315 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SCHROEDERS CAPITAL PRIVATE EQUITY ASIA MAURITIUS IV LIMITED, UP TO 7,912,322 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY TWENTY NINE CAPITAL PARTNERS LIMITED PARTNERSHIP (ACTING AT ALL TIMES THROUGH ITS GENERAL PARTNER, TWENTY NINE CAPITAL PARTNERS (GENERAL PARTNER) LIMITED), UP TO 6,532,434 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ACCEL INDIA V (MAURITIUS) LIMITED, UP TO 6,165,096 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ACCEL INDIA IV (MAURITIUS) LIMITED, UP TO 16,021,780 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MUKESH BANSAI, UP TO 16,212,631 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY BRUNO EDUARD RASCHLE, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY JAMES SHA, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ASAF AVIDAN ANTONIR, UP TO 907,287 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY KARAN HARESH MOTWANI, UP TO 907,284 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY NEHA KARAN MOTWANI, UP TO 633,813 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY HRITHIK RAKESH ROSHAN, UP TO 610,000 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY GUL RAMCHAND ADVANI, UP TO 467,335 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VILAS S DHAR, UP TO 211,245 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MUKUL DEORAS, UP TO 138,016 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VIJAY KUMAR TAPARIA, UP TO 49,849 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SHRADHA SHETH, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY NIKHIL KAKKAR (THE "INDIVIDUAL SELLING SHAREHOLDERS") COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS", AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE", AND TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A PRE-IPO PLACEMENT OF SPECIFIED SECURITIES AGGREGATING UP TO ₹1,900.00 MILLION, AS MAY BE PERMITTED UNDER THE APPLICABLE LAW, AT ITS DISCRETION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER, OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND THE PROSPECTUS AND DETAILS OF THE PRE-IPO PLACEMENT, IF ANY, SHALL BE REPORTED TO THE STOCK EXCHANGES WITHIN 24 HOURS OF SUCH TRANSACTIONS, IN ACCORDANCE WITH REGULATION 54 OF THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company in consultation with the BRLMs and each of the Selling Shareholders, may for reasons to be recorded in writing, extend the Bid Offer Period for a minimum of one Working Day, subject to the Bid Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and intimation to Self-Certified Syndicate Banks ("SCSBs"), the Designated Intermediaries (as defined hereinafter) and the Sponsor Banks, (as defined hereinafter) as applicable.

This is an Offer in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. This Offer is being made through the Book Building Process in compliance with Regulation 6(2) of the SEBI ICDR Regulations wherein in terms of Regulation 32(2) of the SEBI ICDR Regulations not less than 75% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") and such portion of the "QIB Portion" provided that our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"). 40% of the Anchor Investor Portion shall be reserved as follows: (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds and Life Insurance Companies and Pension Funds at or above the price at which Equity Shares will be allocated to Anchor Investors ("Anchor Investor Allocation Price") in accordance with the SEBI ICDR Regulations and any under-subscription of 6.67% of the Anchor Investor Portion reserved for Life Insurance Companies and Pension Funds, such under-subscription portion may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be allotted to QIBs, then the entire Bid Amount (as defined hereinafter) will be refunded forthwith. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Offer shall be available for allocation to NBIs of which (a) one third portion shall be reserved for Bidders with application size of more than ₹20 million and up to ₹1.00 million; and (b) two-thirds of the portion shall be reserved for Bidders with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to Bidders in other sub-category of the NBIs in accordance with SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, not more than 10% of the Offer shall be available for allocation to Retail Individual Bidders ("RIB") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts (including UPI ID (defined hereinafter) in case of UPI Bidders (defined hereinafter) using the UPI Mechanism (defined hereinafter)), in which case the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable to participate in the Offer. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" on page 536 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP, on July 7, 2026 with the Stock Exchanges and Securities and Exchange Board of India ("SEBI"). Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of publication of this public announcement by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE at www.bseindia.com and NSE at www.nseindia.com, on the website of the Company at www.cult.fit, and on the websites of the Book Running Lead Managers ("BRLMs"), i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jeffries.com, www.mfi.com and www.morganstanley.com, respectively. Our Company invites the public to give their comments on the DRHP filed with SEBI and the Stock Exchanges, with respect to disclosures made in the DRHP. The public is requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Offer on or before 5:00 p.m. on the 21st day from the date of publication of this public announcement in accordance with Regulation 26(2) of the SEBI ICDR Regulations.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" beginning on page 21 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when issued through the RHP, are proposed to be listed on the Stock Exchanges.

For details of the share capital and capital structure and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, please see the section titled "Capital Structure" on page 104 of the DRHP. The liability of the members of our Company is limited by their shares. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on page 298 of the DRHP.

BOOK RUNNING LEAD MANAGERS					REGISTRAR TO THE OFFER
Axis Capital Limited 1 st Floor, Axis House P.B. Marg Worli Mumbai - 400 025 Maharashtra, India Tel: +91 22 4325 2183 E-mail: cultfit ipo@axiscap.in Website: www.axiscapital.co.in Investor Grievance ID: complaints@axiscap.in Contact Person: Pavan Naik SEBI Registration Number: INM000012029	Goldman Sachs (India) Securities Private Limited 10 th Floor Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai - 400 025 Maharashtra, India Tel: +91 22 6616 9000 E-mail: gs-cultfit@gs.com Website: www.goldmansachs.com Investor Grievance ID: india-client-support@gs.com Contact Person: Achint Parmarandaria/Harsh Parekh SEBI Registration Number: INM000011054	Jefferies India Private Limited Level 16, Express Towers, Nariman Point, Mumbai - 400 021, Maharashtra, India Tel: +91 22 4356 6000 E-mail: Cultfit.IPO@jefferies.com Website: www.jeffries.com Investor Grievance ID: jipl.grievance@jefferies.com Contact Person: Nidhi Rana, Vriti Menghrajani SEBI Registration Number: INM000011443	JM Financial Limited 7 th Floor, Energy, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025 Maharashtra, India Tel: +91 22 6630 3030 E-mail: cultfit.ipo@jmf.com Website: www.jmf.com Investor grievance ID: grievance.ipo@jmf.com Contact Person: Prachee Dhuri SEBI Registration No: INM000010361	Morgan Stanley India Company Private Limited Altimus, Level 39 & 40, Pandurang Burchkar Marg, Worli, Mumbai - 400 018 Maharashtra, India Tel: +91 22 6118 1000 E-mail: cultfitipo@morganstanley.com Website: www.morganstanley.com Investor Grievance ID: investors_india@morganstanley.com Contact Person: Aditi Heega SEBI Registration No: INM000011203	KFin Technologies Limited 301, The Centrum, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Kurla, Mumbai - 400 070, Maharashtra, India Tel: +91 40 6716 2222/180003094001 E-mail: cultfit.ipo@kfintech.com Website: www.kfintech.com Investor grievance e-mail: elnwardns@kfintech.com Contact Person: M. Murali Krishna SEBI Registration No.: INR000002021

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For **CULT.FIT LIMITED**
 (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)
 On behalf of the Board of Directors
 Sd/-
Siddharth Sharma
 Company Secretary and Compliance Officer

Place: Chennai
 Date: July 7, 2026

CULT.FIT LIMITED (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited) is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on July 7, 2026. The DRHP is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.cult.fit, and on the websites of the BRLMs, i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jeffries.com, www.jmf.com and www.morganstanley.com, respectively. Any potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" on page 21 of the DRHP. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, when filed, for making any investment decision.

This announcement is not for publication or distribution to persons in the United States. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act ("Rule 144A")) and referred to in the Draft Red Herring Prospectus as "U.S. QIBs", for the avoidance of doubt, the term U.S. QIBs does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the Draft Red Herring Prospectus as "QIBs" in one or more transactions exempt from the registration requirements of the U.S. Securities Act, and (ii) outside the United States in "offshore transactions", as defined in, and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.



Utkarsh Small Finance Bank
Aapki Ummeed Ka Khaata
 (A Scheduled Commercial Bank)
UTKARSH SMALL FINANCE BANK LIMITED
 CIN: L65992UP2016PLC082804
 Registered Office: Utkarsh Tower, NH - 31 (Airport Road), Sehmalpur, Kazi Sarai, Harhua, Varanasi, Uttar Pradesh, PIN - 221105.
 Tel. No.: +91-542-6605555 | Email: shareholders@utkarsh.bank.in
 Website: www.utkarsh.bank.in

NOTICE IS HEREBY GIVEN THAT THE TENTH (10th) ANNUAL GENERAL MEETING ("AGM") OF THE MEMBERS OF UTKARSH SMALL FINANCE BANK LIMITED ("USFBL" OR "THE BANK") WILL BE HELD ON TUESDAY, AUGUST 04, 2026 AT 2.30 P.M., INDIAN STANDARD TIME ("IST") THROUGH VIDEO CONFERENCE ("VC") / OTHER AUDIO-VISUAL MEANS ("OAVM") TO TRANSACT THE BUSINESS AS SET OUT IN THE NOTICE OF THE AGM WHICH WILL BE CIRCULATED FOR CONVENING THE AGM.

- This is in compliance with the applicable provisions of the Companies Act, 2013 and the Rules made thereunder and Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") read with the Ministry of Corporate Affairs, Government of India ("MCA") Circular No. 03/2025 dated September 22, 2025 (in continuation with the Circulars issued earlier in this regard) ("MCA Circulars") and the SEBI vide various circulars issued in this regard ("SEBI Circulars") has permitted companies to hold AGM through VC or OAVM, without physical presence of the Members at a common venue.
- The Notice of AGM and Annual Report of the Bank for the Financial Year 2025-26 will be sent electronically to those Members whose e-mail addresses are registered with the Bank/ Registrar and Transfer Agent ("RTA") i.e. KFin Technologies Limited ("KFIN") or with the Depository Participant ("DP"). The Bank shall send a physical copy of the Annual Report to those Members who request for the same at shareholders@utkarsh.bank.in mentioning their DP ID and Client ID.
- All the shares of the Bank are Dematerialized form. Members holding shares in Dematerialized form and who have not registered/updated their e-mail addresses with the Depository Participants are requested to register/update their e-mail addresses and mobile numbers with their DP by following procedures prescribed by their DP.
- The Bank has engaged the services of National Securities Depository Limited ("NSDL") for the purpose of providing e-voting facility to its Members to cast their votes on all resolutions set out in the Notice of 10th AGM. The details such as manner of (i) registering/updating email addresses, (ii) casting vote through remote e-voting/e-voting during the AGM and (iii) attending the AGM through VC/OAVM will be set out in the Notice of the AGM, which will be circulated through e-mail. The remote e-Voting facility would be available during the following period:

Commencement of e-Voting	Saturday, August 01, 2026 at 9:00 a.m. (IST)
End of e-Voting	Monday, August 03, 2026 at 5:00 p.m. (IST)

For Utkarsh Small Finance Bank Limited
 Sd/-
Muthiah Ganapathy
 Company Secretary & Compliance Officer
 Date: July 08, 2026
 Place: Mumbai

CONCORD BIOTECH
Biotech for Mankind...
CONCORD BIOTECH LIMITED
 CIN : L24230GJ1984PLC007440
 Regd. Off.: 1482-86, Trasad Road, Dholka, Ahmedabad - 382225, Gujarat, India
 Tel. No.: +91-79-68138725 | Email: compliance@concordbiotech.com
 Website: https://www.concordbiotech.com

NOTICE OF THE 41ST ANNUAL GENERAL MEETING, BOOK CLOSURE AND REMOTE E-VOTING INFORMATION

Notice is hereby given that the 41st Annual General Meeting ("AGM") of the Members of the Company will be held on **Friday, July 31, 2026 at 12:00 Noon** through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the business as set out in the Notice of AGM. The Company has sent the Annual Report along with Notice convening 41st AGM on Tuesday, July 07, 2026, through electronic mode to all the Members whose e-mail IDs are registered with the Company's Registrar & Share Transfer Agent, M/s MUFG Intime India Private Limited / Depository Participant(s). In accordance with the provisions of the Companies Act, 2013 ("the Act"), read with the Rules made thereunder and General Circular Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 5, 2020 and subsequent circulars issued in this regard, the latest being 03/2025 dated September 22, 2025, collectively referred to as "MCA Circulars", and other applicable circulars issued by the Securities and Exchange Board of India (SEBI) including Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024 ("SEBI Circulars"). AGM of the Company is being held through VC / OAVM.

In accordance with the aforesaid Circulars, Notice of AGM along with the Annual Report 2025-26 has been sent only by electronic mode to those Members whose e-mail addresses are registered with the Company/ Depositories. The Company has also sent a letter containing the web-link along with the path to access the Annual Report 2025-26 (including the Notice) to the Members whose email addresses are not registered with the Company/ RTA/ Depository Participant(s) pursuant to Regulation 36(1)(b) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (Listing Regulations). Members may note that the Notice of AGM and Annual Report 2025-26 is also available at the Company's website i.e., www.concordbiotech.com, website of Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and on the website of the Central Depository Services (India) Limited (agency providing remote e-voting facility and e-voting facility during the AGM) i.e., www.evotingindia.com. Members can attend and participate in the AGM through the VC / OAVM facility only. The instructions for joining the AGM are provided in the Notice of the AGM. Members attending the meeting through VC / OAVM shall be counted for the purpose of reckoning the quorum as per Section 103 of the Companies Act, 2013.

Notice is also hereby given that pursuant to Regulation 42 of Listing Regulations, the Company has fixed record date as Friday, July 24, 2026 for the purpose of identification of shareholders to whom dividend is to be paid and for the purpose of 41st AGM of the Company. Pursuant to the provisions of Section 108 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended and Regulation 44 of the Listing Regulations, members are provided with the facility to cast their vote electronically through remote e-voting as e-voting during the AGM services provided by the Central Depository Services (India) Limited on all resolutions as set forth in the 41st AGM Notice. The voting rights of the members shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as on Friday, July 24, 2026 ("cut-off date").

The remote e-voting period commences on Tuesday, July 28, 2026 (09:00 A.M. IST) and ends on Thursday, July 30, 2026 (05:00 P.M. IST). During this period, the Members may cast their votes electronically. The remote e-voting module shall be disabled by the Central Depository Services (India) Limited thereafter. Those Members, who shall be present in the AGM through VC / OAVM facility and had not cast their votes on the Resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.

The members who have cast their votes by remote e-voting prior to the AGM may also attend/participate in the AGM through VC/OAVM but shall not be entitled to cast their votes again.

Any person, who acquires shares of the Company and becomes a Member of the Company after the Notice has been sent electronically by the Company and holds shares as on the cut-off date, may obtain the log in ID and password by sending a request to helpdesk.helpdesk.evoting@cdsindia.com. However, if he/she is already registered with CDSL for remote e-voting, then he/she can use his/her existing User ID and password for casting the votes.

The manner of remote e-voting and voting at the AGM by members holding shares in dematerialized mode, physical mode and process to register e-mail addresses for members who have not registered their email addresses is provided in the Notice of the 41st AGM.


In case Member(s) have not registered their e-mail addresses with the Company/ Depository, please follow the below instructions to register e-mail address for obtaining Annual Report and login details for e-voting - Members holding shares in Demat mode can get their E-mail ID registered by contacting their respective Depository Participant or by e-mail to complianceofficer@concordbiotech.com

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdsindia.com or contact at toll free no. 18002109911.

For **CONCORD BIOTECH LIMITED**
 Sd/- **Paritosh Trivedi**
 Company Secretary & Compliance Officer (ACS : 63623)
 Place : Ahmedabad
 Date : July 07, 2026

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES OR UNITS NOR IS IT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES OF CULT.FIT LIMITED (FORMERLY CULT.FIT PRIVATE LIMITED AND CUREFIT HEALTHCARE PRIVATE LIMITED) ON THE MAIN BOARD OF BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES" IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT



CULT.FIT LIMITED

(Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)

Our Company was originally incorporated as 'Cure Fit Healthcare Private Limited' as a private limited company under the Companies Act, 2013, at Bengaluru, Karnataka, pursuant to a certificate of incorporation dated May 24, 2016 issued by the Registrar of Companies, Central Registration Centre ("CRC"). Subsequently, the name of the Company changed to 'CureFit Healthcare Private Limited' pursuant to a Board resolution dated September 22, 2016 and special resolution passed by the Shareholders dated September 23, 2016 on account of re-branding 'CureFit' for branding and marketing purposes, and a fresh certificate of incorporation dated November 16, 2016 issued by the Registrar of Companies, Karnataka at Bangalore. Further, the name of the Company changed to 'Cult.Fit Private Limited' pursuant to a Board resolution dated March 3, 2026 and special resolution passed by the Shareholders dated March 13, 2026 on account of re-branding 'Cult.Fit' to reflect our Company's business identity and branding strategy, and a fresh certificate of incorporation dated April 29, 2026 issued by the Registrar of Companies, Central Processing Centre ("CPC"). Our Company was thereafter converted into a public limited company pursuant to a resolution passed by our Board on June 16, 2026 and resolution passed by our Shareholders on June 17, 2026 and the name of our Company changed to 'Cult.Fit Limited'. A fresh certificate of incorporation dated June 25, 2026 was issued by the CPC pursuant to conversion to a public limited company. For further details, including details in relation to the changes in the registered office of our Company, see "History and Certain Corporate Matters - Changes in our Registered Office" on page 295 of the draft red herring prospectus dated July 6, 2026 ("DRHP").

Corporate Identity Number: U74989TN2016PLC176669
 Registered Office: 3rd Floor, Plot No. 269, Sy. No. 439/1B, Rajiv Gandhi Road, Chennai, Sholinganallur, Saidapet, Kanchipuram - 600 119, Tamil Nadu, India
 Corporate Office: CureFit HQ, 17/17C - BDA, 18th Cross, Sector-3, HSR Layout, Bengaluru, - 560 102, Karnataka
 Tel: +91 9187219018; Website: www.cult.fit; Contact person: Siddharth Sharma, Company Secretary and Compliance Officer; E-mail: secretnal@cult.fit

OUR COMPANY IS A PROFESSIONALLY MANAGED COMPANY AND DOES NOT HAVE AN IDENTIFIABLE PROMOTER

INITIAL PUBLIC OFFERING OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF CULT.FIT LIMITED ("OUR COMPANY" OR "THE COMPANY") FOR CASH AT A PRICE OF ₹[•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[•] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[•] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹9,500.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 178,609,200 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS CONSISTING OF UP TO 24,664,113 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY MACRITCHIE INVESTMENTS PTE. LTD., UP TO 19,537,242 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY FITNESS FIRST LUXEMBOURG S.C.A., UP TO 17,038,233 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY IIG VENTURES INDIA FUND III LLC, UP TO 15,862,353 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY TATA DIGITAL PRIVATE LIMITED, UP TO 11,056,131 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY CHIRATAE TRUST REPRESENTED BY ITS TRUSTEE VISTRAL ITC (INDIA) LIMITED AND ACTING THROUGH ITS INVESTMENT MANAGER, NAIGAMA INVESTMENT MANAGER LLP, UP TO 9,915,315 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY SCHROEDERS CAPITAL PRIVATE EQUITY ASIA MAURITIUS IV LIMITED, UP TO 7,912,322 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY TWENTY NINE CAPITAL PARTNERS LIMITED PARTNERSHIP (ACTING AT ALL TIMES THROUGH ITS GENERAL PARTNER, TWENTY NINE CAPITAL PARTNERS (GENERAL PARTNER) LIMITED), UP TO 6,532,434 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY ACCEL INDIA V (MAURITIUS) LIMITED, UP TO 6,165,096 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY ACCEL INDIA IV (MAURITIUS) LIMITED, UP TO 6,021,780 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY MUKESH BANSAI, UP TO 16,212,631 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY BRUNO EDUARD RASCHLE, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY JAMES SHA, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY ASAF AVIDAN ANTONIR, UP TO 907,287 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY KARAN HARESH MOTWANI, UP TO 907,284 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY NEHA KARAN MOTWANI, UP TO 633,813 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY HRITHIK RAKESH ROSHAN, UP TO 610,000 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY GUL RAMCHAND ADVANI, UP TO 467,335 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY VILAS S DHAR, UP TO 211,245 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY MUKUL DEORAS, UP TO 138,016 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY VIJAY KUMAR TAPARIA, UP TO 49,849 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY SHRADDHA SHETH, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[•] MILLION BY NIKHIL KAKKAR (THE "INDIVIDUAL SELLING SHAREHOLDERS") COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS", AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE", AND TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A PRE-IPO PLACEMENT OF SPECIFIED SECURITIES AGGREGATING UP TO ₹1,900.00 MILLION, AS MAY BE PERMITTED UNDER THE APPLICABLE LAW, AT ITS DISCRETION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER, OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND THE PROSPECTUS AND DETAILS OF THE PRE-IPO PLACEMENT, IF ANY, SHALL BE REPORTED TO THE STOCK EXCHANGES WITHIN 24 HOURS OF SUCH TRANSACTIONS, IN ACCORDANCE WITH REGULATION 54 OF THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company in consultation with the BRLMs and each of the Selling Shareholders, may for reasons to be recorded in writing, extend the Bid Offer Period for a minimum of one Working Day, subject to the Bid Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and intimation to Self-Certified Syndicate Banks ("SCSBs"), the Designated Intermediaries (as defined hereinafter) and the Sponsor Banks, (as defined hereinafter) as applicable.

This is an Offer in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. This Offer is being made through the Book Building Process in compliance with Regulation 6(2) of the SEBI ICDR Regulations wherein in terms of Regulation 32(2) of the SEBI ICDR Regulations not less than 75% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") and such portion of the "QIB Portion" provided that our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"). 40% of the Anchor Investor Portion shall be reserved as follows: (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds and Life Insurance Companies and Pension Funds at or above the price at which Equity Shares will be allocated to Anchor Investors ("Anchor Investor Allocation Price") in accordance with the SEBI ICDR Regulations and any under-subscription of 6.67% of the Anchor Investor Portion reserved for Life Insurance Companies and Pension Funds, such under-subscription portion may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be allotted to QIBs, then the entire Bid Amount (as defined hereinafter) will be refunded forthwith. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Offer shall be available for allocation to NBIs of which (a) one third portion shall be reserved for Bidders with application size of more than ₹20 million and up to ₹1.00 million; and (b) two-thirds of the portion shall be reserved for Bidders with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to Bidders in other sub-category of the NBIs in accordance with SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, not more than 10% of the Offer shall be available for allocation to Retail Individual Bidders ("RIB") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts (including UPI ID (defined hereinafter) in case of UPI Bidders (defined hereinafter) using the UPI Mechanism (defined hereinafter)), in which case the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable to participate in the Offer. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" on page 536 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP, on July 7, 2026 with the Stock Exchanges and Securities and Exchange Board of India ("SEBI"). Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of publication of this public announcement by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE at www.bseindia.com and NSE at www.nseindia.com, on the website of the Company at www.cult.fit, and on the websites of the Book Running Lead Managers ("BRLMs"), i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jeffries.com, www.mfi.com and www.morganstanley.com, respectively. Our Company invites the public to give their comments on the DRHP filed with SEBI and the Stock Exchanges, with respect to disclosures made in the DRHP. The public is requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Offer on or before 5:00 p.m. on the 21st day from the date of publication of this public announcement in accordance with Regulation 26(2) of the SEBI ICDR Regulations.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" beginning on page 21 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when issued through the RHP, are proposed to be listed on the Stock Exchanges.

For details of the share capital and capital structure and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, please see the section titled "Capital Structure" on page 104 of the DRHP. The liability of the members of our Company is limited by their shares. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on page 298 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER	
Axis Capital Limited 1 st Floor, Axis House P.B. Marg Worli Mumbai - 400 025 Maharashtra, India Tel: +91 22 4325 2183 E-mail: cultfit ipo@axiscap.in Website: www.axiscapital.co.in Investor Grievance ID: complaints@axiscap.in Contact Person: Pavan Naik SEBI Registration Number: INM000012029	Goldman Sachs (India) Securities Private Limited 10 th Floor Ascent-Worli, Sudam Kulu Ahire Marg, Worli, Mumbai - 400 025 Maharashtra, India Tel: +91 22 6616 9000 E-mail: gs-cultfit@gs.com Website: www.goldmansachs.com Investor Grievance ID: india-client-support@gs.com Contact Person: Achint Parmarandaria/ Harsh Parekh SEBI Registration Number: INM000011054	Jefferies India Private Limited Level 16, Express Towers, Nariman Point, Mumbai - 400 021, Maharashtra, India Tel: +91 22 4356 6000 E-mail: Cultfit.IPO@jefferies.com Website: www.jeffries.com Investor Grievance ID: jipl.grievance@jefferies.com Contact Person: Nidhi Rana, Vrini Menghrajani SEBI Registration Number: INM000011443	JM Financial Limited 7 th Floor, Energy, Appasaheb Marathe Marg, Prabhadevi Mumbai - 400 025 Maharashtra, India Tel: +91 22 6630 3030 E-mail: cultfit.ipo@jmf.com Website: www.jmf.com Investor grievance ID: grievance.ipo@jmf.com Contact Person: Prachee Dhuri SEBI Registration No: INM000010361	Morgan Stanley India Company Private Limited Altimus, Level 39 & 40, Pandurang Burchkar Marg, Worli, Mumbai - 400 018 Maharashtra, India Tel: +91 22 6118 1000 E-mail: cultfitipo@morganstanley.com Website: www.morganstanley.com Investor Grievance ID: investors_india@morganstanley.com Contact Person: Aditi Herga SEBI Registration No: INM000011203	KFin Technologies Limited 301, The Centrum, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Kurla, Mumbai - 400 070, Maharashtra, India Tel: +91 40 6716 2222/18003094001 E-mail: cultfit.ipo@kfnitech.com Website: www.kfnitech.com Investor grievance e-mail: elnw@kfnitech.com Contact Person: M. Murali Krishna SEBI Registration No.: INR030002021

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For **CULT.FIT LIMITED**
 (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)
 On behalf of the Board of Directors
 Sd/-
Siddharth Sharma
 Company Secretary and Compliance Officer

CULT.FIT LIMITED (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited) is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on July 7, 2026. The DRHP is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.cult.fit; and on the websites of the BRLMs, i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jeffries.com, www.jmf.com and www.morganstanley.com, respectively. Any potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" on page 21 of the DRHP. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, when filed, for making any investment decision.

This announcement is not for publication or distribution to persons in the United States. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act ("Rule 144A")) and referred to in the Draft Red Herring Prospectus as "U.S. QIBs"; for the avoidance of doubt, the term U.S. QIBs does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the Draft Red Herring Prospectus as "QIBs" in one or more transactions exempt from the registration requirements of the U.S. Securities Act, and (ii) outside the United States in "offshore transactions", as defined in, and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.

Utkarsh Small Finance Bank
Aapki Ummeed Ka Khaata
 (A Scheduled Commercial Bank)
UTKARSH SMALL FINANCE BANK LIMITED
 CIN: L65992UP2016PLC082804
 Registered Office: Utkarsh Tower, NH - 31 (Airport Road), Sehmalpur, Kazi Sarai, Harhua, Varanasi, Uttar Pradesh, PIN - 221105.
 Tel. No.: +91-542-660555 | Email: shareholders@utkarsh.bank.in
 Website: www.utkarsh.bank.in

NOTICE IS HEREBY GIVEN THAT THE TENTH (10th) ANNUAL GENERAL MEETING ("AGM") OF THE MEMBERS OF UTKARSH SMALL FINANCE BANK LIMITED ("USFB" OR "THE BANK") WILL BE HELD ON TUESDAY, AUGUST 04, 2026 AT 2.30 P.M., INDIAN STANDARD TIME ("IST") THROUGH VIDEO CONFERENCE ("VC") / OTHER AUDIO-VISUAL MEANS ("OAVM") TO TRANSACT THE BUSINESS AS SET OUT IN THE NOTICE OF THE AGM WHICH WILL BE CIRCULATED FOR CONVENING THE AGM.

- This is in compliance with the applicable provisions of the Companies Act, 2013 and the Rules made thereunder and Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") read with the Ministry of Corporate Affairs, Government of India ("MCA") Circular No. 03/2025 dated September 22, 2025 (in continuation with the Circulars issued earlier in this regard) ("MCA Circulars") and the SEBI vide various circulars issued in this regard ("SEBI Circulars") has permitted companies to hold AGM through VC or OAVM, without physical presence of the Members at a common venue.
 - The Notice of AGM and Annual Report of the Bank for the Financial Year 2025-26 will be sent electronically to those Members whose e-mail addresses are registered with the Bank/ Registrar and Transfer Agent ("RTA") i.e. KFin Technologies Limited ("KFIN") or with the Depository Participant ("DP"). The Bank shall send a physical copy of the Annual Report to those Members who request for the same at shareholders@utkarsh.bank.in mentioning their DP ID and Client ID.
 - All the shares of the Bank are Dematerialized form. Members holding shares in Dematerialized form and who have not registered/updated their e-mail addresses with the Depository Participants are requested to register/update their e-mail addresses and mobile numbers with their DP by following procedures prescribed by their DP.
 - The Bank has engaged the services of National Securities Depository Limited ("NSDL") for the purpose of providing e-voting facility to its Members to cast their votes on all resolutions set out in the Notice of 10th AGM. The details such as manner of (i) registering/ updating email addresses, (ii) casting vote through remote e-voting/e-voting during the AGM and (iii) attending the AGM through VC/OAVM will be set out in the Notice of the AGM, which will be circulated through e-mail. The remote e-Voting facility would be available during the following period:
- | | |
|--------------------------|--|
| Commencement of e-Voting | Saturday, August 01, 2026 at 9:00 a.m. (IST) |
| End of e-Voting | Monday, August 03, 2026 at 5:00 p.m. (IST) |
- The Members are requested to carefully read all the Notes set out in the Notice of 10th AGM (being sent electronically) and particulars, instructions for joining AGM and manner of casting vote through remote e-voting or e-voting at the AGM.
 - The Notice of 10th AGM and the Annual Report for Financial Year 2025-26 will also be made available on the Bank's website www.utkarsh.bank.in and websites of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and also on the website of NSDL at www.evoting.nsdl.com
- For Utkarsh Small Finance Bank Limited
 Sd/-
Muthiah Ganapathy
 Company Secretary & Compliance Officer
- Date: July 08, 2026
 Place: Mumbai

CONCORD BIOTECH
Biotech for Mankind...
CONCORD BIOTECH LIMITED
 CIN : L24230GJ1984PLC007440
 Regd. Off.: 1482-86, Trasad Road, Dhokla, Ahmedabad - 382225, Gujarat, India
 Tel. No.: +91-79-68138725 | Email : compliance@concordbiotech.com
 Website : https://www.concordbiotech.com

NOTICE OF THE 41ST ANNUAL GENERAL MEETING, BOOK CLOSURE AND REMOTE E-VOTING INFORMATION

Notice is hereby given that the 41st Annual General Meeting ("AGM") of the Members of the Company will be held on **Friday, July 31, 2026 at 12:00 Noon** through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the business as set out in the Notice of AGM.

The Company has sent the Annual Report along with Notice convening 41st AGM on Tuesday, July 07, 2026, through electronic mode to all the Members whose e-mail IDs are registered with the Company's Registrar & Share Transfer Agent, M/s MUGF Intime India Private Limited / Depository Participant(s).

In accordance with the provisions of the Companies Act, 2013 ("the Act"), read with the Rules made thereunder and General Circular Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 5, 2020 and subsequent circulars issued in this regard, the latest being 03/2025 dated September 22, 2025, collectively referred to as "MCA Circulars", and other applicable circulars issued by the Securities and Exchange Board of India (SEBI) including Circular No. SEBI/HO/CFD/CFO-PoD-2/P/CIR/2024/133 dated October 3, 2024 ("SEBI Circulars"). AGM of the Company is being held through VC / OAVM.

In accordance with the aforesaid Circulars, Notice of AGM along with the Annual Report 2025-26 has been sent only by electronic mode to those Members whose e-mail addresses are registered with the Company/ Depositories. The Company has also sent a letter containing the web-link along with the path to access the Annual Report 2025-26 (including the Notice) to the Members whose email addresses are not registered with the Company/ RTA/ Depository Participant(s) pursuant to Regulation 36(1)(b) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (Listing Regulations). Members may note that the Notice of AGM and Annual Report 2025-26 is also available at the Company's website i.e. www.concordbiotech.com, website of Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and on the website of the Central Depository Services (India) Limited (agency providing remote e-voting facility and e-voting facility during the AGM) i.e. www.evotingindia.com. Members can attend and participate in the AGM through the VC / OAVM facility only. The instructions for joining the AGM are provided in the Notice of the AGM. Members attending the meeting through VC / OAVM shall be counted for the purpose of reckoning the quorum as per Section 103 of the Companies Act, 2013.

Notice is also hereby given that pursuant to Regulation 42 of Listing Regulations, the Company has fixed record date as Friday, July 24, 2026 for the purpose of identification of shareholders to whom dividend is to be paid and for the purpose of 41st AGM of the Company. Pursuant to the provisions of Section 108 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended and Regulation 44 of the Listing Regulations, members are provided with the facility to cast their vote electronically through remote e-voting or e-voting during the AGM services provided by the Central Depository Services (India) Limited on all resolutions as set forth in the 41st AGM Notice. The voting rights of the members shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as on Friday, July 24, 2026 ("cut-off date").

The remote e-voting period commences on Tuesday, July 28, 2026 (09:00 A.M. IST) and ends on Thursday, July 30, 2026 (05:00 P.M. IST). During this period, the Members may cast their vote electronically. The remote e-voting module shall be disabled by the Central Depository Services (India) Limited thereafter. Those Members, who shall be present in the AGM through VC/OAVM facility and had not cast their votes on the Resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.

The members who have cast their votes by remote e-voting prior to the AGM may also attend/participate in the AGM through VC/OAVM but shall not be entitled to cast their votes again.

Any person, who acquires shares of the Company and becomes a Member of the Company after the Notice has been sent electronically by the Company and holds shares as on the cut-off date, may obtain the login ID and password by sending a request to helpdesk@concordbiotech.com. However, if he/she is already registered with CDSL for remote e-voting, then he/she can use his/her existing User ID and password for casting the votes.

The manner of remote e-voting and voting at the AGM by members holding shares in dematerialized mode, physical mode and process to register e-mail addresses for members who have not registered their email addresses is provided in the Notice of the 41st AGM.

In case Member(s) have not registered their e-mail addresses with the Company/ Depository, please follow the below instructions to register e-mail address for obtaining Annual Report and login details for e-voting -

Members holding shares in Demat mode can get their E-mail ID registered by contacting their respective Depository Participant or by e-mail to compliance@concordbiotech.com

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdsindia.com or contact at toll free no. 18002109911.

For **CONCORD BIOTECH LIMITED**
 Sd/- **Paritosh Trivedi**
 Company Secretary &
 Compliance Officer (ACS : 53623)

Place : Ahmedabad
 Date : July 07, 2026

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES OR UNITS NOR IS IT A PROSPECTUS. ANNOUNCEMENT, NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES OF CULT.FIT LIMITED (FORMERLY CULT.FIT PRIVATE LIMITED AND CUREFIT HEALTHCARE PRIVATE LIMITED) ON THE MAIN BOARD OF BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES" IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").

PUBLIC ANNOUNCEMENT



CULT.FIT LIMITED

(Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)



(Please scan this QR code to view the Draft Red Herring Prospectus)

Our Company was originally incorporated as 'Cure Fit Healthcare Private Limited' as a private limited company under the Companies Act, 2013, at Bengaluru, Karnataka, pursuant to a certificate of incorporation dated May 24, 2016 issued by the Registrar of Companies, Central Registration Centre ("CRC"). Subsequently, the name of the Company changed to 'CureFit Healthcare Private Limited' pursuant to a Board resolution dated September 22, 2016 and special resolution passed by the Shareholders dated September 23, 2016 on account of re-branding 'CureFit' for branding and marketing purposes, and a fresh certificate of incorporation dated November 16, 2016 issued by the Registrar of Companies, Karnataka at Bengaluru. Further, the name of the Company changed to 'Cult.Fit Private Limited' pursuant to a Board resolution dated March 3, 2026 and special resolution passed by the Shareholders dated March 13, 2026 on account of re-branding 'Cult.Fit' to reflect our Company's business identity and branding strategy, and a fresh certificate of incorporation dated April 29, 2026 issued by the Registrar of Companies, Central Processing Centre ("CPC"). Our Company was thereafter converted into a public limited company pursuant to a resolution passed by our Board on June 16, 2026 and resolution passed by our Shareholders on June 17, 2026 and the name of our Company changed to 'Cult.Fit Limited'. A fresh certificate of incorporation dated June 25, 2026 was issued by the CPC pursuant to conversion to a public limited company. For further details, including details in relation to the changes in the registered office of our Company, see "History and Certain Corporate Matters - Changes in our Registered Office" on page 298 of the draft red herring prospectus dated July 6, 2026 ("DRHP").

Corporate Identity Number: U74999TN2016PLC176689
Registered Office: 3rd Floor, Plot No. 269, Sy. No. 439/1B, Rajiv Gandhi Road, Chennai, Sholinganallur, Saidapet, Kanchipuram - 600 119, Tamil Nadu, India
Corporate Office: Curefit HQ, 17/17C - BDA, 18th Cross, Sector-3, HSR Layout, Bengaluru, - 560 102, Karnataka
Tel: +91 9187219018, **Website:** www.cult.fit, **Contact person:** Siddharth Sharma, Company Secretary and Compliance Officer; **E-mail:** secretarial@cult.fit

OUR COMPANY IS A PROFESSIONALLY MANAGED COMPANY AND DOES NOT HAVE AN IDENTIFIABLE PROMOTER

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF CULT.FIT LIMITED ("OUR COMPANY" OR "THE COMPANY") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹9,500.00 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 178,609,200 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS CONSISTING OF UP TO 24,684,113 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MACRITCHE INVESTMENTS PTE. LTD., UP TO 19,597,242 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY FITNESS FIRST LUXEMBOURG S.C.A., UP TO 17,038,233 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY IOG VENTURES INDIA FUND III LLC, UP TO 15,862,353 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY TATA DIGITAL PRIVATE LIMITED, UP TO 11,056,131 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY CHIRATAE TRUST REPRESENTED BY ITS TRUSTEE VISTRA ITC (INDIA) LIMITED AND ACTING THROUGH ITS INVESTMENT MANAGER, NAIGAMA INVESTMENT MANAGER LLP, UP TO 9,915,315 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SCHROEDERS CAPITAL PRIVATE EQUITY ASIA MAURITIUS IV LIMITED, UP TO 7,912,322 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY TWENTY NINE CAPITAL PARTNERS LIMITED PARTNERSHIP (ACTING AT ALL TIMES THROUGH ITS GENERAL PARTNER, TWENTY NINE CAPITAL PARTNERS (GENERAL PARTNER) LIMITED), UP TO 6,532,434 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ACCEL INDIA V (MAURITIUS) LIMITED, UP TO 6,165,096 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ACCEL INDIA IV (MAURITIUS) LIMITED, UP TO 5,222,078 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY EPIO CAPITAL B, L.P., UP TO 4,130,615 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY KALAARI CAPITAL PARTNERS III, L.L.C., UP TO 3,278,461 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY KALAARI CAPITAL PARTNERS OPPORTUNITY FUND, L.L.C., UP TO 2,316,969 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VAL.ECHA INVESTMENTS PRIVATE LIMITED, UP TO 1,160,568 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SATYADHARMA INVESTMENTS AND TRADING COMPANY PRIVATE LIMITED, UP TO 1,024,116 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY CASTLE INVESTMENT AND INDUSTRIES PRIVATE LIMITED, UP TO 941,781 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ANANTH SANKARANARAYANAN FAMILY TRUST, UP TO 816,061 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SUN N SANDS HOTELS PRIVATE LIMITED, UP TO 729,958 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VENKTESH INVESTMENT AND TRADING COMPANY PRIVATE LIMITED, UP TO 686,412 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ENDIYA SEED CO-CREATION FUND (A SCHEME OF ENDIYA TRUST, ACTING THROUGH ITS TRUSTEE, ENDIYA TRUSTEE PRIVATE LIMITED), UP TO 641,784 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY EXTREME BRANDS LLP, UP TO 486,609 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ONYX SHAREHOLDERS LLC, UP TO 363,065 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY DOLI TRADING AND INVESTMENTS PRIVATE LIMITED (THE "INVESTOR SELLING SHAREHOLDERS"), UP TO 16,021,780 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MUKESH BANSAL, UP TO 10,212,631 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY BRUNO EDUARD RASCHLE, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY JAMES SHA, UP TO 3,904,323 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY ASAF AVIDAN ANTONIR, UP TO 907,287 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY KARAN HARESH MOTWANI, UP TO 907,284 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY NEHA KARAN MOTWANI, UP TO 633,813 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY HRITHIK RAKESH ROSHAN, UP TO 610,000 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY GUL RAMCHAND ADVANI, UP TO 467,333 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VILAS S DHAR, UP TO 211,245 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY MUKUL DEORAS, UP TO 138,016 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY VIJAY KUMAR TAPARIA, UP TO 49,849 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY SHRADHA SHETH, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY PRASHANT SUDHAKAR MACHWE, UP TO 49,800 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹[●] MILLION BY NIKHIL KAKKAR (THE "INDIVIDUAL SELLING SHAREHOLDERS") (COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS", AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE", AND TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A PRE-IPO PLACEMENT OF SPECIFIED SECURITIES AGGREGATING UP TO ₹1,900.00 MILLION, AS MAY BE PERMITTED UNDER THE APPLICABLE LAW, AT ITS DISCRETION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE, PRIOR TO THE COMPLETION OF THE OFFER. OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER, OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND THE PROSPECTUS AND DETAILS OF THE PRE-IPO PLACEMENT, IF ANY, SHALL BE REPORTED TO THE STOCK EXCHANGES WITHIN 24 HOURS OF SUCH TRANSACTIONS, IN ACCORDANCE WITH REGULATION 54 OF THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company in consultation with the BRLMs and each of the Selling Shareholders, may for reasons to be recorded in writing, extend the Bid Offer Period for a minimum of one Working Day, subject to the Bid Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and intimation to Self-Certified Syndicate Banks ("SCSBs"), the Designated Intermediaries (as defined hereinafter) and the Sponsor Banks, (as defined hereinafter) as applicable.

This is an Offer in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. This Offer is being made through the Book Building Process in compliance with Regulation 6(2) of the SEBI ICDR Regulations wherein in terms of Regulation 32(2) of the SEBI ICDR Regulations not less than 75% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") and such portion of the "QIB Portion" provided that our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"). 40% of the Anchor Investor Portion shall be reserved as follows: (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds and Life Insurance Companies and Pension Funds at or above the price at which Equity Shares will be allocated to Anchor Investors ("Anchor Investor Allocation Price") in accordance with the SEBI ICDR Regulations and any under-subscription of 6.67% of the Anchor Investor Portion reserved for Life Insurance Companies and Pension Funds, such under-subscribed portion may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be allotted to QIBs, then the entire Bid Amount (as defined hereinafter) will be refunded forthwith. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Offer shall be available for allocation to NBIs of which (a) one third portion shall be reserved for Bidders with application size of more than ₹20 million and up to ₹1.00 million; and (b) two-thirds of the portion shall be reserved for Bidders with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to Bidders in other sub-category of the NBIs in accordance with SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, not more than 10% of the Offer shall be available for allocation to Retail Individual Bidders ("RIB") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts (including UPI ID (defined hereinafter) in case of UPI Bidders (defined hereinafter) using the UPI Mechanism (defined hereinafter)), in which case the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable to participate in the Offer. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" on page 536 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP, on July 7, 2026 with the Stock Exchanges and Securities and Exchange Board of India ("SEBI"). Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of publication of this public announcement by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE at www.bseindia.com and NSE at www.nseindia.com, on the website of the Company at www.cult.fit; and on the websites of the Book Running Lead Managers ("BRLMs"), i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jefferies.com, www.jmfi.com and www.morganstanley.com, respectively. Our Company invites the public to give their comments on the DRHP filed with SEBI and the Stock Exchanges, with respect to disclosures made in the DRHP. The public is requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Offer on or before 5.00 p.m. on the 21st day from the date of publication of this public announcement in accordance with Regulation 26(2) of the SEBI ICDR Regulations.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" beginning on page 21 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when issued through the RHP, are proposed to be listed on the Stock Exchanges.

For details of the share capital and capital structure and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, please see the section titled "Capital Structure" on page 104 of the DRHP. The liability of the members of our Company is limited by their shares. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on page 298 of the DRHP.

BOOK RUNNING LEAD MANAGERS					REGISTRAR TO THE OFFER
Axis Capital Limited 1 st Floor, Axis House P.B. Marg Worli Mumbai - 400 025 Maharashtra, India Tel: +91 22 4325 2183 E-mail: cultfit ipo@axiscap.in Website: www.axiscapital.co.in Investor Grievance ID: complaints@axiscap.in Contact Person: Pavan Naik SEBI Registration Number: INM000012029	Goldman Sachs (India) Securities Private Limited 10 th Floor Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai - 400 025 Maharashtra, India Tel: +91 22 6616 9000 E-mail: gs-cultfit@gs.com Website: www.goldmansachs.com Investor Grievance ID: india-client-support@gs.com Contact Person: Achnit Parmar/Anandkhar Harsh Parekh SEBI Registration Number: INM000011054	Jefferies India Private Limited Level 16, Express Towers, Nariman Point, Mumbai - 400 021, Maharashtra, India Tel: +91 22 4356 6000 E-mail: Cultfit.IPO@jefferies.com Website: www.jefferies.com Investor Grievance ID: jpl.grievance@jefferies.com Contact Person: Nidhi Rana, Vrili Menhrajani SEBI Registration Number: INM000011443	JM Financial Limited 7 th Floor, Energy, Appasaheb Marathe Marg, Prabhadevi Mumbai - 400 025 Maharashtra, India Tel: +91 22 6630 3030 E-mail: cultfit.ipo@jmfi.com Website: www.jmfi.com Investor grievance ID: grievance.lbd@jmfi.com Contact Person: Prachee Dhuri SEBI Registration No: INM000010361	Morgan Stanley India Company Private Limited Altimus, Level 39 & 40, Pandurang Buidhkar Marg, Worli, Mumbai - 400 018 Maharashtra, India Tel: +91 22 6118 1000 E-mail: cultfitipo@morganstanley.com Website: www.morganstanley.com Investor Grievance ID: investors_india@morganstanley.com Contact Person: Adith Herga SEBI Registration No.: INM000011203	KFIN Technologies Limited 301, The Centrum, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Kurla, Mumbai - 400 070, Maharashtra, India Tel: +91 40 6716 2222/18003094001 E-mail: cultfit.ipo@kfintech.com Website: www.kfintech.com Investor grievance e-mail: einward@kfintech.com Contact Person: M. Murali Krishna SEBI Registration No.: INR000000221

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For **CULT.FIT LIMITED**
 (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited)
 On behalf of the Board of Directors
 Sd/-
Siddharth Sharma
 Company Secretary and Compliance Officer

Place: Chennai
 Date: July 7, 2026

CULT.FIT LIMITED (Formerly Cult.Fit Private Limited and CureFit Healthcare Private Limited) is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on July 7, 2026. The DRHP is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.cult.fit; and on the websites of the BRLMs, i.e. Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, JM Financial Limited and Morgan Stanley India Company Private Limited at www.axiscapital.co.in, www.goldmansachs.com, www.jefferies.com, www.jmfi.com and www.morganstanley.com, respectively. Any potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" on page 21 of the DRHP. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, when filed, for making any investment decision.

This announcement is not for publication or distribution to persons in the United States. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act ("Rule 144A")) and referred to in the Draft Red Herring Prospectus as "QIBs", for the avoidance of doubt, the term U.S. QIBs does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the Draft Red Herring Prospectus as "QIBs" in one or more transactions exempt from the registration requirements of the U.S. Securities Act; and (ii) outside the United States in "offshore transactions", as defined in, and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.